Growth Hormone Splicing and Treatment of Disease Using RNA Interference by Shariat, Nikki
GROWTH HORMONE SPLICING AND TREATMENT OF DISEASE USING RNA 
INTERFERENCE 
By 
Nikki Shariat 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
In partial fulfillment of the requirements 
For the degree of 
DOCTOR OF PHILOSOPHY 
in 
Biological Sciences 
May 2008 
Nashville, Tennessee 
 
Approved: 
James G. Patton, PhD   
Todd R. Graham, PhD 
John A. Phillips III, MD 
Ronald B. Emeson, PhD 
Katherine L. Friedman, PhD 
 
 ii 
 
 
 
 
 
 
 
To my parents, Thamineh and Hashem, 
thank you for your continual support, 
encouragement  and love. 
To Sean, having you by my side  
made this possible, thank you 
 
 
 
 
 
 
 
 
 
 
 
 iii 
ACKNOWLEDGEMENTS 
 
There are many people who have contributed to my success in graduate 
school and have helped me mature both as a scientist and as a person.  First 
and foremost, I would like to thank my advisor, Dr. James G. Patton for your 
support, guidance and patience; I am fortunate to have been mentored by you.  I 
would like to thank our two main collaborators, Dr. Iain C.A.F. Robinson and Dr. 
John A. Phillips III; thank you for your significant input and advice in this work 
and also to members of your labs for their assistance.  I would also like to thank 
each of the members of my thesis committee, Dr. Todd R. Graham, chair, Dr. 
John A. Phillips III, Dr. Ronald B. Emeson and Dr. Katherine L. Friedman for their 
advice and encouragement.  I would like to thank all members of the Patton lab, 
both past and present, you have provided a wonderful and stimulating 
environment to work in.  For those who made direct contributions to this work, I 
would like to thank Cindy Holladay, Melissa Prince and Ryan Cleary, it was a 
pleasure working with you.  In addition, I would like to thank Elvin A. Woodruff III 
for the electron microscopy and Jennifer Skelton and the Vanderbilt Transgenic 
Mouse Core for all their help.  I would also like to thank the staff of the Biological 
Sciences department for all that they do for the graduate students, it does not go 
unnoticed.  There have been many friends and family without whose support and 
encouragement graduate school would have been impossible, thank you. 
This work was supported by NIH grant DK 035592 and also by funds from 
the Vanderbilt Mouse Metabolic Phenotyping Center (DK 59637). 
 iv 
TABLE OF CONTENTS 
 
             Page 
 
DEDICATION........................................................................................................ ii 
ACKNOWLEDGEMENTS .................................................................................... iii 
LIST OF TABLES................................................................................................ vii 
LIST OF FIGURES..............................................................................................viii 
LIST OF ABBREVIATIONS...................................................................................x 
Chapter 
I. INTRODUCTION........................................................................................1 
 
 Splicing.......................................................................................................2 
  Splice site selection .........................................................................2 
  Spliceosome assembly ....................................................................5 
  Splicing reaction ..............................................................................7 
  Alternative splicing...........................................................................8 
  Splicing enhancers ........................................................................12 
  Splicing in disease.........................................................................14 
 RNA interference......................................................................................15 
  Small interfering RNAs ..................................................................17 
  MicroRNAs ....................................................................................17 
  Therapeutic RNAi ..........................................................................19 
  Therapeutic RNAi effector molecules ............................................19 
  siRNA design.................................................................................21 
  Stability of siRNAs .........................................................................24 
  RNAi delivery.................................................................................25 
  Viral delivery of shRNAs ................................................................25 
  Non-selective delivery of siRNAs...................................................26 
  Selective delivery of siRNAs..........................................................30 
  Clinical trials ..................................................................................32 
 Growth hormone.......................................................................................33 
  Anterior pituitary hormones............................................................34 
  Growth hormone genetics..............................................................35 
  Growth hormone secretion ............................................................36 
  Regulation of growth hormone secretion .......................................39 
 v 
  Growth hormone signaling pathway...............................................39 
  Physiological effects of growth hormone .......................................41 
  Growth hormone deficiency ...........................................................41 
  Growth hormone splicing ...............................................................43 
  Mouse model of isolated growth hormone deficiency type II .........48 
  RNA interference as a therapy for IGHD II ....................................52 
 
 
II. ISOLATED GROWTH HORMONE DEFICIENCY TYPE II CAUSED  
BY A DOUBLE ENCRYPTED GH-1 MUTATION THAT HAS  
UNEXPECTED EFFECTS........................................................................54 
 
 Summary..................................................................................................55 
 Introduction...............................................................................................56 
 Subjects and methods..............................................................................59 
  Subjects.........................................................................................59 
  Cell culture and in vivo splicing analyses.......................................59 
  In vitro splicing analysis .................................................................61 
  Electroporation of siRNAs..............................................................61 
 Results .....................................................................................................64 
  A weak 3’ splice site increases exon skipping ...............................64 
  Splicing analysis in patient-derived lymphoblastoid cell lines ........67 
  Disruption of ESE 1 and exon 3 skipping.......................................68 
  RNAi in lymphoblastoid cell lines...................................................70 
 Discussion ................................................................................................71 
  Exon 3 skipping and disease severity............................................71 
  Code within a code within a code ..................................................74 
  Potential therapeutic role of RNAi in IGHD II .................................75 
 Acknowledgements ..................................................................................76 
 
 
III. RESCUE OF PITUITARY FUNCTION IN A MOUSE MODEL OF 
ISOLATED GROWTH HORMONE DEFICIENCY TYPE II BY RNAI........77 
 
 Abstract ....................................................................................................78 
 Introduction...............................................................................................79 
 Materials and methods .............................................................................81 
  Cell culture.....................................................................................81 
  RT-PCR.........................................................................................81 
  Western blots.................................................................................82 
  Transgenic mice ............................................................................82 
  Pituitary dissections.......................................................................83 
  Immunohistochemistry and imaging ..............................................83 
  Electron microscopy ......................................................................84 
  IGF-1 serum analysis.....................................................................84 
  Statistical analysis .........................................................................86 
 vi 
 Results .....................................................................................................86 
  Allele specific targeting of mutant GH-1 transcripts by RNAi .........86 
  Generation of shRNA-17.5 transgenic mice ..................................87 
  Rescue of IGHD II in vivo by RNAi ................................................91 
  Morphological rescue of IGHD II....................................................95 
  Silencing of the 17.5-kDa isoform..................................................97 
 Discussion ................................................................................................99 
 Acknowledgements ................................................................................101 
 
 
IV. SUMMARY AND CONCLUSIONS .........................................................103 
  
 Significance ............................................................................................103 
 Impact and future directions ...................................................................105 
  Phenotypic characterization of rescue mice ................................105 
  Pituitary hormone content............................................................105 
  Effects on bone length and mass.................................................108 
  Developing siRNA-17.5 as a therapeutic .....................................108 
  Time of delivery ...........................................................................109 
  Delivery of siRNAs to the pituitary ...............................................111 
 Mechanism of the dominant negative function of the 17.5-kDa  
 isoform.........................................................................................114 
  RNAi in the pituitary.....................................................................115 
 Summary................................................................................................117 
 
 
REFERENCES..................................................................................................118 
 
 
  
 
 
 
 
 
 
 
 
 vii 
LIST OF TABLES 
 
Table                     Page 
1.  Splice site consensus sequences...............................................................4 
2. Clinical characteristics of subject I-II ........................................................63 
3. Generation of transgenic shRNA-17.5 mice .............................................89 
4. Statistical analysis ....................................................................................93 
5. Statistical analysis ....................................................................................93 
6. Statistical analysis ....................................................................................93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
LIST OF FIGURES 
 
Figure           Page 
1.  Splicing reaction .........................................................................................3 
2. Spliceosome assembly...............................................................................6 
3. Types of alternative splicing with disease-related examples ....................11 
4. RNAi pathway and expression of exogenous RNAi effector molecules....16 
5. RNAi effector molecules...........................................................................20 
6. Increasing stability and efficacy of siRNAs...............................................28 
7. GH-1 alternative splicing pattern ..............................................................44 
8. Regulation of GH-1 exon 3 inclusion ........................................................46 
9. IGHD II pathogenesis ...............................................................................51 
10. Identification of a heterozygous mutation in GH-1 that causes IGHD II....62 
11. E3+1 G→A causes an increase in skipping of exon 3..............................66 
12. E3+1 G→A disrupts enhancer function ....................................................69 
13. Specific targeting of ∆3 transcripts in patient lymphoblastoid lines by 
 RNAi .........................................................................................................72 
14. Allele specific RNAi in AtT-20 cells...........................................................85 
15. Generation of transgenic shRNA-17.5 mice .............................................88 
16. Mating strategy.........................................................................................90 
17. Rescue of IGHD II mice............................................................................92 
18. Morphological rescue of IGHD II ..............................................................96 
19. Silencing of the 17.5-kDa isoform.............................................................98 
20. Analysis of pituitary hormone contents...................................................106 
 ix 
21. IGHD II mice exhibit ER defects at a young age ....................................110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
LIST OF ABBREVIATIONS 
 
∆3  GH-1 transcripts lacking exon 3 
20R  Rescue mice co-expressing ∆3 and shRNA-17.5 (sh-20 line) 
25R  Rescue mice co-expressing ∆3 and shRNA-17.5 (sh-25 line) 
AAV  Adeno-associated virus 
ACTH  Adrenocorticotropic hormone 
AtT-20 Mouse adrenocorticotropic hormone secreting cell line  
BBB  Blood brain barrier 
bp  Base pairs 
BPS  Branch point sequence 
cDNA  Complementary DNA 
DCSV  Dense core secretory vesicles 
dsRNA Double stranded RNA 
DSX  Drosophila doublesex gene 
EM  Electron micrograph 
ER  Endoplasmic reticulum  
ESE  Exonic splicing enhancer 
GH  Growth hormone 
GH-1   Human growth hormone gene 
GH3  Rat somatotroph cell line 
GHD  Growth hormone deficiency 
GHR  Growth hormone receptor 
 xi 
GHRH Growth hormone releasing hormone 
hGH  Human growth hormone 
hnRNP Heterogeneous nuclear ribonucleoproteins 
IGF-1  Insulin-like growth factor 1 
IGHD  Isolated growth hormone deficiency 
IGHD I Isolated growth hormone deficiency type I 
IGHD II Isolated growth hormone deficiency type II 
ISE  Intronic splicing enhancer 
kb  Kilobase 
kDa  Kilodalton 
LH  Luteinizing hormone 
LCR  Locus control region 
miRNA microRNA 
NMD  Nonsense-mediated mRNA decay 
nt  Nucleotide 
OTE  Off target effect 
PEG  Polyethyleneglycol 
PEI  Polyethylenimine 
PCR  Polymerase chain reaction 
Pit-1  Pituitary-specific transcription factor 
PRL  Prolactin 
PTC  Premature termination codon 
Py  Polypyrimindine tract 
 xii 
RISC  RNA-induced silencing complex 
RNAi  RNA interference 
RNP  Ribonucleoprotein 
RRM  RNA recognition motif 
RT  Reverse transcription 
RT-PCR Reverse transcriptase PCR 
shRNA Short hairpin RNA 
shRNA-17.5 Short hairpin RNA targeting the GH-1 transcript encoding 17.5-kDa 
isoform 
 
sh-20  Transgenic shRNA-17.5 mouse line #20 
sh-25  Transgenic shRNA-17.5 mouse line #25 
siRNA  Small interfering RNA 
siRNA-17.5 Small interfering RNA targeting the GH-1 transcript encoding 17.5-
kDa isoform 
 
snRNA Small nuclear RNA 
snRNP Small nuclear ribonucleoprotein 
SR protein Serine-arginine protein 
ssRNA Single stranded RNA 
TSH  Thyroid stimulating hormone 
U2AF  U2 snRNP auxiliary factor 
UTR  Untranslated region 
wt  Wild type 
 
 
 1 
CHAPTER I 
 
INTRODUCTION 
 
Splicing is the regulated removal of introns and the concurrent ligation of 
exons to produce mature mRNA transcripts.  Variability in this tightly regulated 
process is responsible for an extraordinarily diverse proteome from a relatively 
small mammalian genome. Alternative splicing can lead to differential exon 
inclusion or exclusion, as can aberrant splicing, and such transcripts therefore 
differ from constitutively spliced transcripts.  Where mistakes in splicing cause 
disease, the resulting mutant transcripts appear to be ideal targets for RNA 
interference (RNAi).  In the case of inappropriate exon inclusion, small interfering 
RNAs (siRNAs) can be targeted to specific exons.  When exon skipping prevails, 
siRNAs can be designed complementary to the specific exon-exon junctions that 
are not present in normal transcripts.  The human growth hormone gene, GH-1, 
nicely illustrates these points.  Constitutive splicing of all 5 exons produces the 
normal hormone but aberrant skipping of exon 3 can lead to the production of a 
dominant negative isoform and associated Isolated Growth Hormone Deficiency 
type II (IGHD II).  This thesis describes research into understanding the causes 
of exon 3 skipping and shows that siRNAs targeting the unique exon 2-exon 4 
sequence in mutant transcripts can prevent onset of IGHD II in a mouse model.   
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Splicing 
 
Splice Site Selection 
The efficient excision of introns and accurate splicing of exons is required 
for mature transcripts to correctly encode protein.  The importance of correct 
splicing cannot be understated: mistakes that make a wrong protein can rob the 
cell of the function of that protein by altering its structure/function or prevent the 
mRNA from even being translated.  Any one of these outcomes could have 
severe negative consequences.  A conserved series of sequence elements are 
recognized by the spliceosome, a macromolecular complex that catalyzes the 
splicing reaction.  These cis-acting signals include the 5’ splice site, 3’ splice site, 
branch point sequence, and polypyrimidine tract (Figure 1).  The consensus 
sequences for these elements are summarized in Table 1.  Importantly, these 
elements are highly conserved in lower eukaryotes, such as the yeast 
Saccharomyces cerevisiae, but not in higher eukaryotes.  It is thought that this 
level of sequence conservation in S. cerevisiae may explain the relative simplicity 
and lack of alternative splicing in yeast and it most likely reflects the small 
number of intron-containing genes (Hodges et al., 1997).  As such, alternative 
splicing is more abundant in higher organisms.  Another difference between 
higher and lower eukaryotes involves the relative size of exons.  In yeast, the 
average length of exons is long, generally greater than 1 kb, though in 
vertebrates they are much shorter (~140 nucleotides, accounting for 1.1% of the 
genome).  Conversely, vertebrate introns are typically large, averaging greater  
 3 
 
 
 
 
 
 
 
 
 
Figure 1. Splicing reaction.  Conserved splicing elements include the 5’ and 3’ 
splice sites and a branch point sequence followed by the polypyrimidine tract.  
Splicing occurs in two sequential trans-esterification reactions, culminating in 
ligation of two exons and removal of an intron lariat, which is debranched and 
degraded. 
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Table 1. Splice site consensus sequences. Consensus splice sites in 
vertebrates and the yeast, S. cerevisiae.  The intron-exon boundary is denoted 
by  and the branch point adenosine is shown in bold. R, purine; Y, pyrimidine; 
N, purine or pyrimidine. 
 
 
 Vertebrates Yeast 
5’ splice site AGGURAGU GUAUGU 
Branch point sequence YNYURAY UACUAAC 
3’ splice site YAGG YAG 
 
 
 
 
 
 
 
 
 5 
than 3 kb in length and representing 25% of the genome whereas their yeast 
counterparts are on average only 250 nucleotides in length (Consortium, 2001; 
Hawkins, 1988; Venter et al., 2001).  This discrepancy in size poses yet another 
conundrum for the splicing machinery in higher eukaryotes: how to define an 
exon within the “sea” of introns (Black, 1995)? 
 
Spliceosome Assembly 
Canonical splices sites are recognized by multiple trans-acting factors, 
most notably five small nuclear ribonucleoprotein (snRNP) complexes.  The core 
components of these complexes are short RNA molecules, snRNAs, which 
associate with common and specific proteins to form snRNPs (Lührmann, 1988; 
Will and Luhrmann, 1997; Will and Lührmann, 2001).  Spliceosome assembly 
results from the sequential and dynamic organization of the snRNPs that 
recognize the cis-acting splicing signals and assemble in a step-wise manner, 
forming discrete complexes culminating in spliceosome formation and catalysis 
of splicing (Figure 2). 
 The first, or early complex, E, is initiated by U1 snRNP recognizing the 5’ 
splice site via base-pairing between the 5’ end of the U1 snRNA and the 5’ splice 
site sequence (Mount et al., 1983; Reed and Palandjian, 1997; Ruby and 
Abelson, 1988; Seraphin and Rosbash, 1989).  Simultaneously, U2 auxiliary 
factor (U2AF) interacts with the polypyrimidine tract and the 3’ splice site through 
its 65-kDa and 35-kDa subunits and splicing factor 1 (SF1) binds to the branch 
point sequence (Krämer and Utans, 1991; Zamore and Green, 1989; Zamore  
 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Spliceosome assembly. Spliceosome assembly occurs in a step-wise 
manner with the formation of four discrete complexes, E, A, B and C.  It is in the 
C complex where the two sequential trans-esterification reactions occur.   
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 and Green, 1991).  The second, or A complex is ATP dependent.  Here, U2AF 
recruits U2 snRNP to base-pair with the branch point sequence (Chabot and 
Steitz, 1987; Das et al., 2000; Query et al., 1994; Ruskin et al., 1988; Valcárcel et 
al., 1996).  U2 snRNA replaces SF1, displacing a protein-RNA interaction in favor 
of an RNA-RNA interaction (Liu et al., 2001).  The next complex, B, forms when 
the U4/U6-U5 tri snRNP is recruited, where U5 snRNA interacts with sequences 
at both the 5’ and 3’ splice sites (Behrens and Lührmann, 1991; Newman et al., 
1995).  It is thought that the interaction of U5 maintains the proximity of these 
sites within the catalytic core of the spliceosome (Sontheimer and Steitz, 1993; 
Wyatt et al., 1992).  The final, catalytic complex, C, involves a series of 
rearrangements of assembled proteins, RNA-protein interactions, and RNA-RNA 
interactions.  These include destabilization of U4/U6 base-pairing, allowing U6 to 
base-pair with the 5’ splice site by displacing U1 and also to interact with U2 
snRNA, forming a U2/U6 helix (Staley and Guthrie, 1999; Wassarman and Steitz, 
1993; Wassarman and Steitz, 1992).  Following these rearrangements, U1 and 
U4 are displaced and the two steps of splicing occur.  
 
Splicing Reaction 
Splicing occurs in two sequential trans-esterification reactions (Figure 1) 
within the catalytic core of the spliceosome (Reed and Palandjian, 1997; Staley 
and Guthrie, 1998).  In the first step, there is a nucleophilic attack on the 
phosphodiester bond at the 5’ splice site by the 2’-hydroxl of the conserved 
branch point adenosine residue to generate a lariat intermediate.  The free 3’-
 8 
hydroxyl of the first exon then attacks the phosphodiester bond at the 3’ splice 
site to link the two exons.  The intron lariat, with a 2’-5’ phosphodiester linkage, is 
released and is subsequently debranched, degraded, and recycled.  The mature 
mRNA is then exported to the cytoplasm and spliceosomal components are 
recycled for new rounds of splicing.   
 
Alternative Splicing 
A surprising result from the human genome sequencing project was that 
the number of estimated genes (30-35,000) turned out to be far fewer than 
originally predicted based on expressed sequence tags (ESTs; 100,000-150,000 
genes) (Consortium, 2001; Venter et al., 2001).  Recent analysis puts the 
number of protein-coding genes at approximately ~20,500 (Clamp et al., 2007).  
Alternative splicing, the regulated process of differential inclusion or exclusion of 
regions of the mRNA, accounts in large part for this discrepancy.  This molecular 
phenomenon is arguably the most important source of proteomic diversity in 
higher eukaryotes with the ability to generate many different protein isoforms 
from a single RNA transcript.   The majority (60-75%) of human and mouse 
genes are subject to alternative splicing (Consortium, 2001; Johnson et al., 2003; 
Kan et al., 2001; Modrek et al., 2001; Zavolan et al., 2003).  Alternative splicing 
analysis of human chromosome 22 has led to estimates that 60% of genes 
produce at least two transcripts (Hide et al., 2001; Modrek and Lee, 2002).  
These estimates are likely conservative; with increased molecular capabilities to 
isolate and sequence cDNAs, it is expected that alternative splicing events will be 
 9 
detected at an even higher frequency.  Interestingly, approximately one-third of 
alternative splicing events introduce premature termination codons (PTCs), which 
cause targeted degradation of transcripts by nonsense-mediated mRNA decay 
(NMD) (Lewis et al., 2003).  In effect, this is an on-off splicing switch, regulated 
by NMD. 
Alternative splicing represents an efficient expansion of the genome by 
producing several functional proteins from a single transcript.  This is 
accomplished via several mechanisms including the use of alternative 5’ or 3’ 
splice sites (also called cryptic splice sites), intron retention, exon skipping or 
inclusion, and selection between mutually exclusive exons (Figure 3).  These 
mechanisms have a variety of consequences, including disease (Figure 3).  
Additionally, alternative splicing events can also occur in a development and/or 
tissue-specific manner (Black, 2003; Lopez, 1998). 
The spliceosome faces a tremendous task in efficiently and accurately 
identifying splice sites.  This challenge is exacerbated in higher eukaryotes as 
exons are much smaller than introns and the splice site signals that define exon-
intron interfaces are poorly conserved (Cartegni et al., 2002).  Additionally, in a 
given transcript, there can be several sequences that represent potential splice 
sites that match consensus sequences better than the bona fide sites.  Such 
sequences are common in introns and define “pseudo-exons,” which are not 
normally included in the mature mRNA (Sun and Chasin, 2000).  The 
spliceosome has to differentiate between these and the correct splicing signals to 
maintain splicing fidelity.  Such degeneracy is a double-edged sword in that 
 10 
 
 
 
 
 
 
Figure 3. Types of alternative splicing with disease-related examples.  (A)  
IGHD II is caused by exon 3 skipping in the GH-1 gene.  There is also a cryptic 
splice site in exon 3 that produces mRNAs lacking the first 45 nucleotides of 
exon 3.  Mutations at the 5’ end of exon 3 can result in loss of this portion of exon 
3 to produe a 20-kDa GH isoform.  (B) Exon 9 of the Wilms’ tumor suppressor 
(WT1) gene has two alternative 5’ splice sites.  These two sites are nine 
nucleotides apart and code for the amino acid sequence KTS.  Normally, the 
proximal 5′ splice site is favored resulting in production of the +KTS isoform.  In 
Fraiser syndrome, mutations inactivate the proximal 5’ splice site and result in –
KTS isoform production (Klamt et al., 1998).  (C) Intron 8 of the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene contains variable length 
poly U,G and poly U tracts downstream of the branch point.  The lengths of these 
tracts affect exon 9 inclusion.  Exclusion causes atypical cystic fibrosis (Noone 
and Knowles, 2001).  (D) The fibroblast growth factor receptor 2 (FGFR2) gene 
has mutually exclusive exons (IIIb and IIIc) which are included in epithelia and 
mesenchyme, respectively.  In prostate cancer, loss of the exon IIIb containing 
isoform in epithelia promotes an epithelial to mesenchymal transition, which 
corresponds to a transition from a well-differentiated tumor to an aggressive 
tumor (Carstens et al., 1997).  (E) Fish-eye disease is caused by a mutation two 
base pairs upstream of the branch point in intron 4 of the lecithin:cholesterol 
acetyltransferase (LCAT) gene, which results in intron 4 retention (Kuivenhoven 
et al., 1996).  For all examples, the wild-type splicing pattern is shown above and 
the aberrant splicing pattern is shown below. 
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these ‘weaker’ splice sites (those conforming less to the consensus sequence) 
allow alternative splicing to occur.  However, as a result, they are harder to 
recognize by the splicing machinery.  The canonical splice site sequences are 
not sufficient for exon definition in a majority of higher organisms (Lim and Burge, 
2001).  To maintain splicing fidelity, additional cis-acting elements are required.  
These include splicing enhancers and silencers that influence splice site choice 
by recruitment of trans-acting factors to the pre-mRNA.  Enhancers promote 
splicing by recruiting a one or more members of a family of serine-arginine-rich 
proteins (SR proteins) whereas silencers typically inhibit splicing via interactions 
with heterogeneous nuclear ribonucleoproteins (hnRNPs) (Burd and Dreyfuss, 
1994; Cartegni et al., 2002; Liu et al., 1998; Smith and Valcarcel, 2000).  The two 
pathways often compete as binding of hnRNPs to silencers can inhibit splicing by 
antagonizing SR proteins and/or snRNPs (Eperon et al., 2000; Mayeda and 
Krainer, 1992; Wang et al., 2006). 
 
Splicing Enhancers 
 Splicing enhancers are short RNA sequences that are most commonly 
recognized by SR proteins to promote spliceosome assembly (Blencowe, 2000; 
Graveley, 2000; Liu et al., 1998).  They promote both constitutive and regulated 
splicing and can reside within exons or introns (exonic splicing enhancers (ESEs) 
or intronic splicing enhancers (ISEs)).  The majority of enhancers comprise short, 
6-10 nucleotide, purine-rich motifs though other types of enhancers have been 
identified (A/C-rich enhancers)  (Blencowe, 2000; Cartegni et al., 2002; Cooper 
 13 
and Mattox, 1997; Coulter et al., 1997; Schaal and Maniatis, 1999).  Enhancers 
have been identified through mutations that block splicing, via computational 
analyses, and through identification of SR protein binding sequences.  Although 
often purine-rich, short, and degenerate, it appears that the specific sequence is 
more important than overall purine content (Tanaka et al., 1994).   
SR proteins play a crucial role for both constitutive and alternative splicing.  
There are ten core SR proteins and each contains one or two N-terminal RNA 
recognition motifs (RRMs) plus a C-terminal RS domain (Birney et al., 1993; Fu, 
1995).  Binding to certain RNA sequences via RRMs determines substrate 
specificity.  The RS domain consists of several arginine-serine dipeptides that 
facilitate protein-protein interactions with core spliceosome components or other 
trans-acting factors (Tacke and Manley, 1999).  Exonic enhancers direct U2AF 
and U2 binding to the 3’ splice site and U1 binding to the 5’ splice site via 
interactions with SR proteins, forming a ‘bridge’ of splicing factors across the 
exon.  This model of exon definition predominates in higher eukaryotes due to 
moderate exon size (50-250 nucleotides) and large intron size (Berget, 1995).  
An intron-definition model exists in organisms with large exons and small introns 
(Kennedy et al., 1998; Sterner et al., 1996).  SR proteins can also stimulate exon 
definition by antagonizing nearby silencers (Kan and Green, 1999).  
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Splicing in Disease 
Mistakes in splicing can cause disease directly, modify the severity of the 
disease phenotype, or be linked to disease susceptibility (Wang and Cooper, 
2007).  It is also becoming apparent that genetic variation affecting splicing 
efficiency contributes significantly to disease.  It is thought that 50-60% of 
mutations that cause disease do so by affecting splicing (Cartegni et al., 2002; 
López-Bigas et al., 2005; Maquat, 2001; Pagenstecher et al., 2006).  Exonic 
mutations are generally thought to be pathogenic due to introduction of missense 
or nonsense mutations or by altering the reading frame and hence the final 
protein product.  However, it is likely that a fraction of these mutations affect 
splicing (Pagani et al., 2005).  Likewise, intronic mutations can also affect 
splicing efficiency though these are rarely analyzed for disease susceptibility 
since introns are non-coding. 
 In addition to mutations within splicing motifs, mutations within essential 
splicing factors can also cause disease.  Two examples are spinal muscular 
dystrophy (SMA) and retinitis pigmentosum (Briese et al., 2005; Mordes et al., 
2006).  Both diseases are caused by mutations in proteins required for snRNP 
assembly and function.  The former results from loss of the SMN-1 protein 
(survival of motor neuron) that is involved in cytoplasmic snRNP assembly.  As a 
result, loss of SMN-1 impairs snRNP production (Winkler et al., 2005).  Complete 
loss of SMN-1 causes SMA.  Retinitis pigmentosum is a common form of 
blindness caused by mutations in one of more than 30 genes including three 
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dominant genes required for U4/U6-U5 tri-snRNP assembly and function 
(Chakarova et al., 2002; McKie et al., 2001; Vithana et al., 2001). 
 Phenotypic variability due to splicing mutations can also influence disease 
severity.  In the CFTR gene, a single nucleotide polymorphism (SNP) in intron 19 
creates a variably spliced exon whose inclusion increases cystic fibrosis severity 
(Chiba-Falek et al., 1998).  In the OAS1 (2’,5’ oligoadenylate synthetase) gene, a 
G→A mutation in intron 6 shifts the 3’ splice site, exacerbating a Type I Diabetes 
phenotype (Field et al., 2005).  Two polymorphisms in the 3’UTR of CTLA-4 
(cytotoxic T lymphocyte antigen 4) cause skipping of exon 3 to produce a soluble 
protein that lacks a critical ligand-binding domain.  Both mutations have been 
implicated in a host of autoimmune diseases such as Graves’ Disease and 
autoimmune hypothyroidism (Ueda et al., 2003).  These examples highlight the 
importance of splicing fidelity to prevent disease and underscore the importance 
of efficient and precise splicing. 
 
RNA Interference 
The molecular phenomenon of RNA interference (RNAi) was first 
characterized a decade ago in Caenorhabditis elegans (Fire et al., 1998) and 
subsequently in mammalian cells (Elbashir et al., 2001).  RNAi uses small RNAs 
to trigger RNA silencing via sequence specific base-pairing with an mRNA to 
induce mRNA degradation or translational repression (Figure 4).  Broadly, there 
are two classes of small RNAs involved in RNAi and they differ based on their 
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Figure 4. RNAi pathway and expression of exogenous RNAi effector 
molecules. Short hairpin RNAs (shRNAs) expressed from a vector are 
transcribed in the nucleus to produce 60-70 nt hairpin precursors, akin to miRNA 
precursors.  These are exported to the cytoplasm where they are cleaved by 
Dicer and are loaded into the RNA-induced silencing complex (RISC) and can 
locate and silence their target mRNA.  Alternatively, ~21 nt siRNAs can be 
introduced directly into the cytoplasm where they can be incorporated into RISC. 
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origin: microRNAs (miRNAs) and siRNAs.  The former are excised from 
endogenous genomic transcripts and the latter are generated from exogenous 
double-stranded RNAs (dsRNAs).  Since its discovery, RNAi has proven to be a 
potent molecular tool for both reverse genetics and for use as a potential 
therapeutic strategy to treat disease. 
 
Small Interfering RNAs 
It is thought that the RNAi machinery evolved as an innate immune 
response to viral attack.  Long viral dsRNAs are cleaved by an RNase III 
enzyme, Dicer, into small 21-25 nt duplexes called siRNAs (Bernstein et al., 
2001; Zamore et al., 2000).  Cleavage by Dicer leaves a characteristic 2 nt 3’ 
overhang on each strand.  In addition, each strand has a 5’ phosphate and a 3’ 
hydroxyl.  One strand of the siRNA duplex, the one exhibiting the lower free 
energy at its 5’ end, is loaded into an RNA-induced silencing complex (RISC) 
(Khvorova et al., 2003; Schwarz et al., 2003).  This guide strand directs silencing 
of complementary mRNAs in a sequence-specific manner by cleavage of the 
mRNA.  Cleavage of the mRNA occurs between bases 10 and 11 relative to the 
5’ end of the siRNA, allowing subsequent degradation of the cleaved mRNA 
(Elbashir et al., 2001; Orban and Izaurralde, 2005).  
 
microRNAs 
miRNAs are an endogenous class of eukaryotic genes whose mature 
product resembles siRNAs.  They function to fine-tune gene expression during 
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development and differentiation (Bartel and Chen, 2004). Primary miRNAs (pri-
miRNAs) are generally transcribed as long RNA polymerase II transcripts (Lee et 
al., 2004) that are cleaved in the nucleus by a microprocessor that includes an 
RNase III enzyme, Drosha, and a dsRNA-binding protein, DCGR8 (Gregory et 
al., 2004; Lee et al., 2003).  The resulting ~70 nt stem-loop product, the 
precursor miRNA (pre-miRNA), is exported to the cytoplasm via the nuclear 
karyopherin, Exportin-5 (Lund et al., 2004; Yi et al., 2003).  The pre-miRNA is 
then cleaved by Dicer, akin to long dsRNAs, to produce small ~22 nt dsRNA 
duplexes (Bernstein et al., 2001).  Importantly, cleavage by both Drosha and 
Dicer at either end of the duplex defines the termini of the mature miRNA and 
leaves 2 nt 3’ overhangs.  In concert with Dicer, TRBP (HIV-1 TAR RNA-binding 
protein) and PACT (protein activator of PKR), the mature miRNA is loaded into 
RISC (Chendrimada et al., 2005; Lee et al., 2006).  RISC is the effector complex 
for RNAi, the catalytic components of which are the Argonaute (AGO) family of 
proteins.  AGO2 is the endonucleolytic component of human RISC and is the 
only catalytically active member of the Argonaute family in mammals (Liu et al., 
2004).  In the case of siRNAs, AGO2 is also responsible for cleaving the 
passenger strand of the siRNA duplex prior to the guide strand loading into RISC 
(Matranga et al., 2005; Rand et al., 2005).  For miRNAs, the passenger strand is 
released. 
 MicroRNAs generally target the 3’ UTRs of mRNAs.  Typically, and unlike 
siRNAs, miRNAs do not exhibit perfect base-pairing with their target mRNA and 
as such it seems that miRNAs function by repressing translation rather than by 
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mRNA cleavage.  These mRNAs accumulate in specific cytoplasmic entities 
known as processing bodies (P-bodies) (Liu et al., 2005).  Transcripts that are 
associated with P-bodies can either be degraded or can return to translation 
(Parker and Sheth, 2007).  On occasion where there is perfect complementarity 
between the miRNA and its target, cleavage of the mRNA ensues (Yekta et al., 
2004).  Nucleotides 2-8 at the 5’ end of the miRNA are referred to as the seed 
region and usually show perfect complementarity with the target mRNA.  It is this 
region of the mature miRNA that appears to be most important for the interaction 
between the two RNA species (Lewis et al., 2005).  Computer algorithms usually 
emphasize seed pairing in identifying potential targets. 
 
Therapeutic RNAi 
 The beauty of the sequence specificity of RNAi is that it lends itself well to 
therapeutic applications since many disorders are caused by inappropriate gene 
expression.  Much research has progressed in this direction as RNAi has the 
potential to treat a multitude of genetic disorders. 
 
Therapeutic RNAi effector molecules 
Exogenous siRNAs can be introduced into cells via two mechanisms, 
each exploiting the endogenous RNAi pathway.  First, siRNAs can be directly 
administered as synthetic 21 nt dsRNA duplexes with 2 nt 3’ overhangs that 
mimic Dicer substrates and are directly incorporated into RISC (Figure 5a).  
Second, vectors expressing short hairpin RNAs (shRNAs) can be delivered to  
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Figure 5. RNAi effector molecules.  (A) siRNAs can be delivered exogenously 
as 21-nt duplexes. (B) shRNAs can be expressed from a Pol III promoter such 
that the 3’ 2-nt overhang is produced by a transcription termination sequence.  
(C) shRNAs can be expressed as long Pol II transcripts expressing one or more 
hairpins.  These hairpins are processed as miRNAs with initial cleavage by 
Drosha.   
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cells (Brummelkamp et al., 2002).  shRNA precursors imitate miRNA precursors 
by forming stem-loop structures recognized by Dicer.  shRNAs can be expressed 
from either Pol II or Pol III promoters (Figure 5b,c).  The former allows tissue 
specific expression.  Additionally, several shRNAs can be expressed from a 
single polycistronic transcript, thus potentially increasing potency by enabling 
knock-down of a single mRNA by different shRNAs (Sarnow et al., 2006).  
Expression from a constitutive Pol III promoter such as H1 or U6 yields a 
transcript that mimics a pre-miRNA and can be directly exported to the cytoplasm 
via Exportin 5 (Kim and Rossi, 2007).  RNAi induced by siRNAs tends to be 
transient, effective only as long as the siRNA is present.  Conversely, RNAi 
triggered by shRNAs is effective for as long as the shRNA continues to be 
transcribed (Brummelkamp et al., 2002; Paddison et al., 2002). 
 
siRNA Design 
The first step in designing therapeutic siRNAs is to identify potential 
sequences that allow knock-down of specific target mRNAs, usually via a 
bioinformatic approach.  This is followed by in vitro testing to determine silencing 
efficacy at the lowest concentration and to eliminate potential off-target effects 
(OTEs; discussed below).   The siRNA strand with lower free energy at its 5’ end 
is incorporated into RISC to activate the complex.  In siRNA drug design, strand 
selection can be manipulated by making a single nucleotide substitution at the 
end of the duplex to favor incorporation into RISC (Schwarz et al., 2003).  More 
potent siRNAs generally have a moderate-to-low GC content (30-52%); if the GC 
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content is too high, there may be difficulty in unwinding and if it is too low it may 
not interact well with its target mRNA (Boese et al., 2005; Reynolds et al., 2004). 
A lack of secondary structure and low internal stability are also characteristics of 
optimal siRNAs (Boese et al., 2005; Reynolds et al., 2004).  It is also desirable to 
design siRNAs against conservesd mRNA sequences (de Fougerolles et al., 
2007).  As an example, the Human Immunodeficiency Virus (HIV) can mutate 
rapidly to evade host immune responses and also RNAi (Scherer et al. 2007).  
Therefore, an siRNA that targets a conserved region of the mRNA can reduce 
this (Naito et al. 2007).  For all siRNAs, regardless of design, innate immune 
responses must be evaded as well as avoiding potential OTEs and saturation of 
endogenous host RNAi components (discussed in depth below).   
In higher vertebrates, the introduction of long dsRNAs (>30 bp) activates 
Protein Kinase R (PKR) and induces an interferon (IFN) response, directing 
cessation of global gene expression (Manche et al., 1992).  There are a limited 
number of reports that small siRNA duplexes can also trigger this innate immune 
response, as Toll-like receptors (TLRs) expressed in endosomes can recognize 
both single- and double-stranded RNAs to elicit an IFN response (Seth et al., 
2006).  In particular TLR3, TLR7 and TLR8 have been shown to activate such a 
response to exogenous siRNAs in vivo in mice and in vitro in human blood 
(Hornung et al., 2005; Kim and Rossi, 2007; Marques and Williams, 2005).  GU-
rich immunostimulatory sequence motifs recognized by TLRs should be avoided 
in siRNA design – 5’-GUCCUUCAA-3’ and 5’-UGUGU-3’ (Hornung et al., 2005; 
Judge et al., 2005).  Immune stimulation by synthetic siRNAs can be completely 
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abrogated by incorporation of 2'-O-methyl uridine or guanosine nucleotides into 
one strand of the siRNA duplex (Judge et al., 2006).   
Avoiding complementarity between the siRNA and untargeted mRNAs is 
the key to avoiding off-target silencing.  miRNA seed sequences usually have 
increased complementarity with the 3’UTR of target mRNAs, copmpared to the 3’ 
end of the miRNA.  As such, particular attention should be addressed in avoiding 
base-pairing between the 5’ region of an siRNA and any off-target mRNAs 
(Birmingham et al., 2006; Jackson et al., 2003; Jackson et al., 2006b).  A recent 
report showed that a simple 2’O-methyl ribosyl substitution at position 2 of the 
guide strand reduced silencing of all partially complementary mRNAs but did not 
affect silencing of the perfectly matched target transcript (Jackson et al., 2006a).  
Grimm and colleagues recently showed that abundant shRNA expression 
using adeno-associated virus (AAV) vectors caused toxicity in mice due to 
saturation of Exportin-5, which prevented nuclear export of endogenous liver 
miRNAs (Grimm et al., 2006).  Lower hepatic expression of shRNAs via AAV-
vectors does not appear to be toxic (Narvaiza et al., 2006).  Expression of 
shRNAs from lentiviral vectors in primary lymphocytes with different Pol III 
promoters demonstrated that expression via U6 caused gradual cytotoxicity 
whereas that by H1 showed reduced expression but no cell death and was still 
able to silence the CCR5 (chemokine receptor-5) target mRNA (An et al., 2006).  
Considering this, siRNAs appear more desirable than shRNAs as they are 
introduced into the RNAi pathway at a later point and therefore are not as likely 
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to be detrimental by causing toxicity due to saturation of endogenous RNAi 
components. 
 
Stability of siRNAs 
Although double stranded, siRNAs are still rapidly degraded by serum 
RNAses with a half-life of minutes in human plasma (Choung et al., 2006; Layzer 
et al., 2004).  Additionally the molecular mass of siRNAs is smaller than the 
threshold for glomerular filtration leading to premature removal by renal 
clearance (Dykxhoorn and Lieberman, 2006).  For use as a viable therapeutic, 
various chemical modifications have recently been developed to increase stability 
and improve efficacy without adversely affecting biological activity.  Importantly, 
Chiu and Rana showed that the 2’-hydroxyl (2’-OH) that differentiates RNA from 
DNA is not required for RNAi (Chiu and Rana, 2003).  Modifications of the 2’-OH 
group have successfully increased persistence of siRNAs compared to non-
modified counterparts.  These include addition of 2’-O-methyl-(2’-O-me)-purines, 
2’-fluoro-(2’-F)-pyrimidines or locked nucleic acid (LNA) nucleotides (Allerson et 
al., 2005; Braasch et al., 2003; Chiu and Rana, 2003; Choung et al., 2006; 
Czauderna et al., 2003; ElmÈn et al., 2005) (Figure 6a,b).  Phosphorothioate 
linkages on the siRNA also increase stability by preventing nuclease activity 
while retaining wild-type activity (Amarzguioui et al., 2003; Choung et al., 2006).  
Extensive modifications of siRNAs against Hepatitis B virus (2’-F on all 
pyrimidines and 2’-O-me on all purines plus a 3’ terminal phosphorothioate 
linkage) increased the half-life from 5 minutes (unmodified) to 3 days in 90% 
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human serum yet still inhibited viral replication (Morrissey et al., 2005a).  Other 
additions include terminal peptide sequences on the siRNAs, which can increase 
both stability and uptake (Chiu et al., 2004).  In most cases, modifications that 
confer exonuclease resistance appear generally well tolerated and silencing 
activity is retained.  Additional stability against nucleases can also occur 
depending on the mode of siRNA delivery and packaging, such as liposomes or 
nanoparticles. 
 
RNAi Delivery 
Efficient and effective delivery of RNAi effector molecules is the most 
challenging obstacle in the development of therapeutic RNAi.  Various methods 
have been developed to deliver both shRNAs and siRNAs. 
 
Viral Delivery of shRNAs 
shRNAs can be produced from viral expression vectors and although this 
gene therapy approach has its limitations, especially regarding safety issues 
(ESGT, 2006; Cavazzana-Calvo and Fischer, 2007), it may be the best option for 
long-term delivery and treatment of chronic diseases (Kim and Rossi, 2007).  
There are three types of viral vectors, each with advantages and disadvantages: 
lentivirus vectors, adenovirus, and adeno-associated virus (AAV).  Lentiviral 
vectors transduce both dividing and non-dividing cells and exert stable shRNA 
expression with broad host tropism (Sumimoto and Kawakami, 2007).  However, 
they require integration of the shRNA transgene into the genome, with potential 
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insertional mutagenic consequences.  shRNA delivery via adenovirus vectors is 
advantageous due to robust shRNA expression and also the potential ability to 
treat cancers by generating tumor-specific variants that conditionally replicate in 
and lyse transformed cells (Yoo et al.).  However, these vectors can be strongly 
immunogenic (Grimm and Kay, 2007).  Adenoviral and AAV vectors express 
transgenes episomally with no or very low (AAV) levels of genomic integration 
(Grimm and Kay, 2007).  AAV vectors efficiently infect a wide variety of dividing 
or quiescent cells and have already been clinically studied in multiple tissues 
(Manno et al., 2006).  The ability to pseudotype shRNA genomes with a huge 
array of AAV capsids (both natural and synthetic) can confer tissue specificity 
(Grimm and Kay, 2003).  Disadvantages to use of adenoviral and AAV vectors 
include somewhat moderate shRNA expression and the necessity for repeat 
administrations that can be strongly immunogenic (Kim and Rossi, 2007). 
 
Non-Selective delivery of siRNAs 
Early RNAi therapeutic studies delivered synthetic siRNAs (or vectors 
encoding shRNAs), using high-pressure, large volume, tail vein injections in mice 
to target these RNAs to the liver, kidney, spleen, pancreas and lung (Lewis et al., 
2002; Lewis and Wolff, 2005; McCaffrey et al., 2002).  The elevated venous 
pressures from this method transiently disrupt the plasma membranes of highly 
vascularized tissues, allowing siRNA uptake (Dykxhoorn and Lieberman, 2006).  
This hydrodynamic approach is not applicable for humans as it has been shown 
to cause right-sided heart failure (Dykxhoorn et al., 2006; McCaffrey et al., 2002). 
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Like all nucleic acids, siRNA duplexes are negatively charged polymers 
and cannot easily penetrate hydrophobic cell membranes (Kim and Rossi, 2007; 
Li et al., 2006).  Systemic delivery of modified siRNAs or siRNAs conjugated to 
cholesterol or packaged within a liposomal particle has been achieved by 
intravenous injection, though this is only clinically relevant if targeting the liver or 
jejunum (Figure 6c,d).  Cholesterol is transported in the circulation via lipoprotein 
particles, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) (Brown 
and Goldstein, 1985).  Conjugation of cholesterol to the 5’ end of the passenger 
strand increased stability of siRNAs targeted to apoplipoprotein B (ApoB) mRNA 
after intravenous injection in mice and led to mRNA reduction in both the liver 
and jejunum (55% and 70%, respectively) (Soutschek et al., 2004).  Recent work 
has shown that mice injected with HDL-cholesterol-siRNA conjugates had an 8-
15 fold greater reduction in ApoB protein in the liver, gut and blood than with just 
cholesterol-siRNA conjugates (Wolfrum et al., 2007).  HDL receptors facilitate 
uptake by the liver, gut, kidney, adrenal glands and ovaries, whereas LDL 
primarily targets the liver.  Null mice lacking the HDL scavenger receptor class B 
type I (SR-BI) exhibit a substantial reduction in cholesterol-siRNA uptake 
(Wolfrum et al., 2007).  HDL-cholesterol-siRNA complexes are large enough to 
avoid renal clearance, increasing the overall stability and efficacy.   
Liposomes are vesicles with an internal aqueous lumen enclosed by a 
phospholipid bilayer.  When liposomes complex with siRNAs or other nucleic 
acids, they are referred to as lipoplexes, which in turn can be further adapted to 
include multiple lipids (de Fougerolles et al., 2007).  An important advance in  
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi
gu
re
 6
. 
In
cr
ea
si
ng
 s
ta
bi
lit
y 
an
d 
ef
fic
ac
y 
of
 s
iR
N
A
s.
 (
A)
, 
(B
) 
C
he
m
ic
al
 m
od
ifi
ca
tio
ns
 s
uc
h 
as
 2
’-O
-
m
et
hy
lp
ur
in
es
 (A
) o
r 2
’-O
-fl
uo
ro
py
rim
id
in
es
 c
an
 b
e 
ad
de
d 
to
 in
cr
ea
se
 s
iR
N
A 
st
ab
ilit
y.
  (
C
) C
ho
le
st
er
ol
 c
an
 
be
 c
on
ju
ga
te
d 
to
 s
iR
N
As
 fo
r 
sy
st
em
ic
 d
el
iv
er
y.
 (
D
) 
si
R
N
As
 c
an
 b
e 
en
ca
ps
ul
at
ed
 w
ith
in
 li
po
so
m
es
 to
 fo
rm
 
st
ab
le
-n
uc
le
ic
-a
ci
d-
lip
id
 p
ar
tic
le
s 
(S
N
AL
Ps
). 
(E
) 
An
 a
nt
ib
od
y-
pr
ot
am
in
e 
fu
si
on
 p
ro
te
in
 c
an
 n
on
co
va
le
nt
ly
 
bi
nd
 s
iR
N
As
 to
 d
el
iv
er
 s
iR
N
As
 to
 s
pe
ci
fic
 c
el
l-s
ur
fa
ce
 re
ce
pt
or
s.
  (
F)
 s
iR
N
As
 li
nk
ed
 to
 a
n 
R
N
A 
ap
ta
m
er
 c
an
 
ta
rg
et
 c
el
ls
 th
at
 e
xp
re
ss
 c
el
l s
ur
fa
ce
 re
ce
pt
or
s 
th
at
 a
re
 re
co
gn
iz
ed
 b
y 
th
e 
ap
ta
m
er
s.
 
 29 
RNAi therapeutics was the first example of siRNA delivery in non-human 
primates.  siRNAs were encapsulated in stable nucleic acid-lipid particles 
(SNALPs) containing fusogenic and cationic lipids and polyethylene glycol (PEG; 
Figure 6d), which, upon injection reduced ApoB mRNA levels in the liver for 11 
days after a single dose (Zimmermann et al., 2006).  Importantly, silencing was 
achieved using a dose 20x less than that mentioned above with cholesterol-
siRNA conjugates (2.5 mgkg-1 in cynomologous monkeys versus 50 mgkg-1 in 
mice) (Soutschek et al., 2004; Zimmermann et al., 2006).  That SNALPs can be 
used to target siRNAs to organs other than the liver has not yet been published.  
Local injection of lipoplexes has been successfully used to deliver siRNAs 
to several organs including the eye, CNS, vagina, lung, intestine and also to 
tumor tissue (Bitko et al., 2005; Bumcrot et al., 2006; Kumar et al., 2006; Luo et 
al., 2005; Masiero et al., 2007; Palliser et al., 2006; Reich SJ, 2003; Tompkins et 
al., 2004; Zhang et al., 2006).  Most of these deliveries involve direct local 
injection of the siRNA with the exception of the lung and vagina.  Delivery to the 
lung to treat respiratory syncytial virus (RSV) or influenza was achieved by 
intranasal instillation (Bitko et al., 2005; Tompkins et al., 2004).  For vaginal 
epithelium delivery, siRNAs were delivered by tissue transfection, mixing the 
siRNAs with a lipid transfection reagent (Palliser et al., 2006). 
Polyethylenimine (PEI) polymers can also be used to deliver siRNAs.  
These polymers are highly cationic and when endocytosed into cells they disrupt 
the endosomal pH, leading to osmotic release of the siRNA-polyplex into the 
cytoplasm (Boussif et al., 1995; de Fougerolles et al., 2007).  PEI-siRNA 
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complexes have been used successfully to treat influenza in mice (Ge et al., 
2004) and Ebola in guinea pigs (Geisbert et al., 2006).  However, at higher 
doses, PEI appears to be extremely toxic (de Fougerolles et al., 2007). 
 
Selective delivery of siRNAs 
Selective siRNA administration is desirable as it could enable a lower drug 
dose, thus reducing potential OTEs in non-target tissues (Kim and Rossi, 2007).  
This has been achieved by packaging siRNAs within nanoparticles coated with 
receptor-targeting ligands or by coupling siRNAs to antibody fragments and 
aptamers (Chu et al., 2006; McNamara et al., 2006; Peer et al., 2007; Song et 
al., 2005; Zhang et al., 2004).  siRNAs are delivered in a cell-specific fashion 
mediated by endocytosis.  
RNA aptamers are RNA ligands that bind to cell surface receptors and can 
be linked to siRNAs either covalently forming an ‘all-RNA’ molecule (McNamara 
et al., 2006) or via modular streptavidin bridges that conjugate biotinylated 
siRNAs (Chu et al., 2006).  The advantage of the former is that the ability of 
specific cell targeting and RNAi are both available from a single RNA molecule 
(Figure 6e).  Although using RNA aptamers may be more simple and flexible, the 
small size of the aptamers (25-35 bases) means it is a viable approach for local 
delivery in vivo but would not be stable unless further conjugated due to renal 
clearance and short half-life (de Fougerolles et al., 2007). 
Another powerful mode of selective systemic delivery involves the use of 
nanoparticles.  Here, siRNAs are complexed with cationic peptides and polymers 
 31 
via interactions with the negative phosphate backbone of the RNA (Juliano, 
2005).  Cell-specific targeting is achieved by coating the nanoparticle with cell-
type-specific ligands.  In one example, transferrin was covalently linked to short 
polycations containing cyclodextrin polymers that provide low toxicity and the 
complex was delivered via low-pressure, low-volume tail vein injections to a 
mouse model of metastatic Ewing’s sarcoma (Hu-Lieskovan et al., 2005).  This 
approach dramatically inhibited tumor growth as compared to control siRNAs in 
transferrin receptor-expressing tumor cells and, importantly, relapse rates were 
low compared to chemotherapy (Hu-Lieskovan et al., 2005).   
In two other cell-specific delivery approaches, either a plasmid encoding 
an shRNA within a PEG-PEI nanoparticle was linked to folate, or siRNAs 
packaged within nanoparticles comprising bacteriophage phi29 pRNA conjugated 
to folate, were used to target nasopharyngeal carcinoma cells which overexpress 
the folate receptor (Guo et al., 2006; Hwa Kim et al., 2005).  In the latter, phi29 
utilizes the 120-bp pRNA to accomplish dsDNA packaging into a preformed 
procapsid (Garver and Guo, 1997).  PEG-PEI nanoparticles containing siRNAs 
have also been conjugated to Arg-Gly-Asp (RGD) peptide ligands to form 
‘nanoplexes’ that target siRNAs to integrin-expressing tumor cells both in 
cultured cells and in vivo (Schiffelers et al., 2004).  
Immunoliposomes, where antibodies are conjugated to liposomes, have 
also been used to confer specificity.  Liposomal complexes encapsulating shRNA 
expression vectors were conjugated to two receptor-specific monoclonal 
antibodies that recognize the human insulin receptor and the mouse transferrin 
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receptor (Zhang et al., 2004).  The target was human epidermal growth factor, 
expressed in human gliomas that were implanted within the brain of mice.  
Receptor-mediated trancytosis across the blood-brain barrier was achieved via 
binding of the mouse transferrin antibody to its receptor and receptor-mediated 
endocytosis via binding of the human insulin antibody and its cognate receptor.  
Weekly injections of these immunoliposomes resulted in a significant increase in 
mouse survival time (Zhang et al., 2004). 
Protamine is a positively charged, arginine-rich protein that binds nucleic 
acids with high affinity and is involved in DNA nucleation in sperm.  In an elegant 
study, heavy chain antibody fragments specific for the HIV gp120 protein were 
conjugated to a protamine fragment bound to siRNAs to selectively deliver 
siRNAs to HIV-infected cells in vivo (Song et al., 2005) (Figure 6f).  In a similar 
approach, an antibody fragment specific to the open conformation of the integrin 
lymphocyte function-associated antigen-1 (LFA-1) was used to deliver siRNAs.  
LFA-1 alters its conformation to an open state only in activated cells and this 
approach specifically targeted activated rather than unstimulated leukocytes 
(Peer et al., 2007). 
 
Clinical Trials 
Currently there are three different RNAi-based therapies that are 
undergoing clinical trials (de Fougerolles et al., 2007).  Two of these, Sirna-027 
(Sirna Pharmaceuticals; Merck) and Cand5 (also known as bevasiranib sodium; 
Opko Health), target vascular endothelial growth factor (VEGF) via intravitrial 
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injection (de Fougerolles et al., 2007).  VEGF plays a pivotal role in ocular 
angiogenesis, causing age-related macular degeneration (AMD) (Bressler, 2004; 
Ferrara, 2002).  Ocular injection is attractive for ease of delivery with the 
additional benefits of fewer nucleases and less protection from the immune 
system.  Cand5 began a phase III trial in July 2007 and siRNA-027 is in phase II 
trials (Perkel, 2007).  The third siRNA trial is ALN-RSV01 (Alnylam), an antiviral 
siRNA that targets RSV, a respiratory viral infection that affects both children and 
adults.  The siRNA targets a viral nucleocapsid gene via intranasal delivery.  
ALN-RSV01 is currently in phase II trials (Perkel, 2007).  Another promising 
RNAi-based strategy is AKIi-5 (Quark and Silence Therapeutics), a modified 
siRNA that prevents acute kidney injury (AKI; also known as acute renal failure).  
AKI develops rapidly (within hours to days) post-surgery with a mortality rate of 
65%.  AKIi-5 targets p53, a transcription factor associated with DNA repair and 
apoptosis.  Temporary inhibition of p53 during AKI delays apoptosis, allowing 
natural repair mechanisms to restore normal DNA and cellular intergrity.  AKli-5 
is expected to enter phase I clinical trials later this year and will be the first 
systemic siRNA tested in humans (Quark Pharmaceuticals, Inc. Press Release - 
http://www.medicalnewstoday.com/articles/89268.php). 
  
In the incredibly short time since the discovery of RNAi, much has been 
accomplished in characterizing and utilizing this powerful mechanism.  That there 
are current clinical trials employing siRNAs only six years after RNAi was first 
observed in mammalian cells is truly astounding and it is possible that RNAi as a 
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treatment for disease may usher in an era similar to the introduction of antibiotics 
in the 20th century. 
 
Growth Hormone 
Growth hormone (GH) is produced in the anterior pituitary gland and 
promotes postnatal growth of bone and muscle.  It is the main determinant of 
longitudinal growth and overall body size (Isaksson et al., 1982). GH, also known 
as somatotropin, is composed of 191 amino acids and is synthesized, stored and 
secreted from somatotrophs, which constitute the major cell type in the anterior 
pituitary.  Regulated expression of GH is essential for normal stature and also for 
homeostasis of carbohydrate, protein and fat metabolism (Gibney et al., 2003; 
Jorgensen et al., 2004; Norrelund et al., 2002; Ohlsson et al., 1998). 
 
Anterior Pituitary Hormones 
The pituitary gland is composed of two distinct units, the anterior pituitary 
(adenohypophysis) and the posterior pituitary (neurohypophysis) that differ in 
morphology and function and also embryologically.  The anterior pituitary is 
derived from an epithelial invagination of the oral mucosa known as Rathke’s 
pouch.  This gland is connected to the hypothalamus by the pituitary stalk, 
allowing communication between the two organs.  Five distinct cell types 
comprise the anterior pituitary and each secretes a specific hormone(s).  These 
are somatotrophs (secrete GH), lactotrophs (prolactin; PRL), corticotrophs 
(adrenocorticotropin; ACTH), thyrotrophs (thyroid-stimulating hormone; TSH) and 
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gonadotrophs (follicle-stimulating hormone; FSH and luteinizing hormone; LH).  
Secretion of these hormones is controlled directly by the hypothalamus and is 
mediated via hypothalamic releasing hormones, which can promote or inhibit 
specific hormone secretion.   
 
Growth Hormone Genetics 
The human GH gene, GH-1, resides within a cluster of highly homologous 
(92-98% nucleotide identity) genes on chromosome 17 (17q23) (Chen et al., 
1989; Procter et al., 1998).  This 66.5 kb cluster is thought to have arisen from a 
series of gene duplications and consists of five genes: GH-1, chorionic 
somatomammotropin genes 1 and 2 (CSH-1 and CSH-2), a chorionic 
somatomammotropin pseuodgene (CSHP-1) and a second GH gene (GH-2) 
(Barsh et al., 1983; Chen et al., 1989; Hirt et al., 1987; Miller and Eberhardt, 
1983).  These genes lie in the same transcriptional orientation and share a 
similar structure of five exons separated by four small introns (Fiddes et al., 
1979; Jacquemin et al., 1990) (Figure 7).  CSH-1, CSH-2 and GH-2 are all 
expressed in the placenta and contribute to fetal growth (Cooke and Liebhaber, 
1995).  GH-2 encodes GH-V (GH-variant) that differs from the protein encoded 
by GH-1 by 13 amino acids.  GH-V replaces pituitary GH in the maternal 
circulation during the second half of pregnancy (Frankenne et al., 1988).  With 
the exception of CSHP, all genes in the cluster encode a 217 amino acid pre-
hormone that is cleaved to yield a mature hormone with 191 amino acids and a 
molecular weight of 22-kDa (Mullis, 2005). 
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 Somatotrophs constitute 40-50% of cells in the anterior pituitary and 3% of 
pituitary transcripts encode GH (Chen et al., 1989).  There are two main 
elements that regulate GH-1 transcription, a highly polymorphic proximal 
promoter (containing at least 16 single nucleotide polymorphisms; SNPs) and a 
locus control region (LCR) (Cooke and Liebhaber, 1995; Giordano et al., 1997; 
Horan et al., 2003; Jones et al., 1995; Wagner et al., 1997).  Several cis-acting 
factors have been implicated in regulation of GH-1 expression, including 
regulatory sequences within the proximal GH-1 promoter.  The most important of 
these are binding sites for the pituitary-specific transcription factor, Pit-1, which 
stimulates GH-1 expression (Mangalam et al., 1989).  Pit-1 regulates important 
differentiating steps during embryological development of the anterior pituitary 
(Theill and Karin, 1993). Pit-1 also regulates the expression of PRL and TSH as 
well as GH.  Differences in the proximal promoter between GH-1 and other 
related genes in the GH cluster are thought to account for the difference in 
expression of these genes (Procter et al., 1998).  The LCR is located between 
7.5–40-kb upstream of GH-1 and is required for expression of all five genes in 
the GH cluster (Ho et al., 2002; Jones et al., 1995; Su et al., 2000).  This region 
also contains binding sites for Pit-1, which are responsible for the high level, 
somatotroph-specific expression of GH-1 (Shewchuk et al., 1999; Shewchuk et 
al., 2002).  
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Growth Hormone Secretion 
Human GH is active as a monomeric globular protein with a molecular 
mass of 22-kDa.  The nascent GH precursor polypeptide is 217 amino acids in 
length and includes an N-terminal signal peptide for translocation into the 
endoplasmic reticulum (ER).  After cleavage of the leader, the remaining 191 
amino acids exist as a single polypeptide with two intramolecular disulfide 
bridges, which fold into a structure containing four anti-parallel α-helices.  The 
first two helices are parallel to each other and anti-parallel to the last pair (Abdel-
Meguid et al., 1987; De Vos et al., 1992).  From the ER, GH is transported to the 
Golgi.  There are two current models for transport through the Golgi body; the 
vesicular model and the cisternal maturation model.  In the former, secretory 
proteins traverse the Golgi via distinct vesicles between cisternae before 
emerging from the trans-Golgi (Dannies, 1999; Dannies, 2001).  In the 
maturation model, newly secreted proteins from the ER align with pre-Golgi 
intermediates and these structures mature into cis-cisternae.  These cisternae 
then ‘mature’ into the medial- and then trans-Golgi cisternae.  The trans-Golgi 
network disintegrates, forming secretory vesicles (Dannies, 1999; Dannies, 2001; 
Rambourg et al., 1992).  
An important aspect of GH secretion, and indeed the secretion of other 
neuroendocrine hormones, is the ability to rapidly secrete hormone in response 
to stimuli.  This is achieved by packaging of concentrated hormone aggregates 
within dense-core secretory vesicles (DCSVs), so called due to their dense 
appearance in electron microscopy (Dannies, 2002).  Aggregation begins in the 
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Golgi and may serve two functions; first to concentrate the GH and also to sort 
secretory granule proteins (Dannies, 2002).  A model for GH aggregation 
suggests it is induced by acidity; the pH from the ER to the trans-Golgi to the 
secretory granule is 7.2, 6 and 5.5, respectively (Anderson and Pathak, 1985; 
Wu et al., 2001).  All cells have an acidic trans-Golgi lumen but hGH and human 
PRL do not form aggregates in cell lines that do not store proteins within 
secretory granules (Lee et al., 2001; Sankoorikal et al., 2002).  The presence of 
both Zn2+ and Cu2+ ions appears relatively specific to the neuroendocrine 
secretory pathway and may be required in addition to low pH (Dannies, 2002; 
Mullis et al., 2002).  hGH contains well-defined Zn2+ binding sites that induce 
dimerization (Cunningham et al., 1991).  Current hypotheses suggest that while 
these aggregates form in the trans-Golgi, soluble proteins that also occupy the 
lumen are removed in vesicles leaving condensed aggregates behind (Dannies, 
2002). 
When GH releasing hormone (GHRH) interacts with its receptor on the 
somatotroph cell surface, it triggers a series of cascades that culminate in an 
influx of intracellular Ca2+, stimulating swelling of DCSV and release of GH 
(Jena et al., 1997; Lin-Su and Wajnrajch, 2002).  After stimulation, DCSVs swell 
and fuse with the porosome, or fusion pore, a basket-like structure within the 
plasma membrane that contains pores open to the external environment 
(Anderson et al., 2004; Jena et al., 2002; Jena et al., 1997; Jeremic et al., 2003). 
At the porosome base t-SNAREs and calcium channels in the membrane 
facilitate the docking and fusion of secretory vesicles (Wheatley 2007).  An 
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increase in pressure causes release of GH, propelling it into the circulatory 
system (Cho et al., 2002a; Jena et al., 2002).  Studies in pigs show that 
stimulated GH cells contain twice the number of both empty and partially filled 
vesicles than resting cells and that the total number of secretory vesicles does 
not alter after release (Lee et al., 2004).  This supports the notion that during 
secretion, DCSVs transiently dock at the fusion pore to release vesicular content, 
refuting the classical theory of total fusion of the secretory granule with the 
plasma membrane (Breckenridge and Almers, 1987; Cho et al., 2002a; Cho et 
al., 2002b; Lee et al., 2004; Valentijn et al., 1999).  
 
Regulation of Growth Hormone Secretion 
GH is secreted from the anterior pituitary in pulsatile bursts that peak at 
night.  Secretion is under the concerted control of three hypothalamic hormones: 
GH releasing hormone (GHRH), somatostatin and grehlin.  GHRH and grehlin 
are positive regulators, stimulating GH release, while somatostatin is a negative 
regulator (Anderson et al., 2004).  GHRH is mainly expressed in the arcuate 
nucleus of the hypothalamus and is released from neurosecretory terminals in 
the median eminence (Frohman and Kineman, 1999).  Ghrelin is a natural ligand 
for the GH-secretagogue receptor, a G protein-coupled receptor, and stimulates 
GH release directly and also by upregulating GHRH (Caminos et al., 2005; 
Kojima et al., 1999).  It is produced by the stomach, small intestine, and central 
nervous system (Lee et al., 2002).  Unlike GHRH, ghrelin does not stimulate 
transcription of GH-1 (Barinaga et al., 1983).  Somatostatin is a cyclic 14- or 28-
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amino acid residue containing peptide that suppresses GH release, but does not 
seem to affect GH synthesis in the somatotroph (Muller et al., 1999).  
Somatostatin itself is regulated by GH and GHRH, forming a feedback loop that 
regulates GH secretion.  
 
Growth Hormone Signaling Pathway 
Once secreted into the circulatory system, GH acts on various target cells 
expressing the GH receptor (GHR), and GH responsiveness is largely dependent 
on GHR expression (Leung et al., 1987).  GHRs are most highly expressed in 
hepatocytes and to a lesser extent in muscle, bone, kidney, mammary gland, 
adipose and embryonic stem cells, among other cell types (Kelly et al., 1991).  
GHRs belongs to the family of hematopoietic cytokine receptors with single-
transmembrane domains with a heavily glycosylated extracellular domain (Cooke 
and Liebhaber, 1995; Cosman, 1993).  The receptor is present as a dimer on the 
cell surface and binds one GH molecule at two distinct sites, surprising since GH 
itself has no apparent symmetry (Brown et al., 2005; De Vos et al., 1992; Harding 
et al., 1996; Ross et al., 2001). GH binding induces a conformational change in 
the GHR, which activates two Janus Kinase 2 (JAK2) molecules.  These in turn 
autophosphorylate multiple tyrosine residues and subsequently phosphorylate 
GHR, thereby initiating several signaling proteins and pathways (Lanning and 
Carter-Su, 2006).  Activation of JAK2 is thought to be a key step in GH signaling 
(Argetsinger et al., 1993).  The activated GHR-JAK2 complex provides a platform 
for the Signal Transducers and Activators of Transcription (Stats) family of 
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proteins.  After binding to this complex, Stats 1, 3, 5a and 5b are phosphorylated 
by JAK2 and subsequently dimerize, translocate to the nucleus, and act as 
transcription factors for a host of GH-related genes (Herrington et al., 2000; 
Kurzer, 2003).  Binding of JAK2 to GHR also activates signal transduction via the 
Mitogen Activated Protein Kinase (MAPK) and phosphatidylinositol 3′-kinase 
(PI3K) pathways (Smit et al., 1999; Zhu et al., 2001).  GH-induced signal 
transduction can also occur independently of the GHR-JAK2 interaction (Zhu et 
al., 2002). 
 Prolonged activation of JAK2 can lead to unwanted cell transformation 
and cancer so it is vital that GH-signaling is precisely regulated.  The Suppressor 
of Cytokines (SOCS) protein family are negative regulators of GH-signaling 
(Lanning and Carter-Su, 2006).  SOCS 1, 2 and 3 achieve this by binding to 
JAK2, inhibiting its activity and targeting ubiquitination of the GHR-JAK2 complex 
(Flores-Morales et al., 2006; Hansen et al., 1999; Ram and Waxman, 1999).  The 
GH signaling pathway is also negatively regulated by many protein tyrosine 
phosphatases (Flores-Morales et al., 2006).  
 
Physiological Effects of Growth Hormone 
A major role of growth hormone in stimulating body growth is to stimulate 
the liver and other tissues to secrete Insulin-like Growth Factor 1 (IGF-1) 
(D'Ercole and Calikoglu, 2001).  IGF-1 is secreted by the liver in response to GH 
stimulation and low serum IGF-1 levels indicate GH deficiency (GHD) 
(Clemmons, 2007).  GH affects a variety of different tissues.  For bone growth, it 
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promotes chondrocyte proliferation (indirectly, via IGF-1) and differentiation 
(directly) (Olney, 2003).  GH is also involved in the regulation of protein, lipid and 
carbohydrate metabolism both directly and via IGF-1 (Moller et al., 2007; 
Norrelund, 2005).  IGF-1 is implicated in muscle growth, stimulating both 
differentiation and proliferation of myoblasts, as well as enhancing amino acid 
uptake and protein synthesis in muscle (Agnusdei and Gentilella, 2005). 
 
Growth Hormone Deficiency 
GHD is thought to occur at a frequency of 1:4,000 to 1:10,000 (Lacey and 
Parkin, 1974; Lindsay et al., 1993; Rona and Tanner, 1977; Vimpani et al., 1977).  
Most cases appear to be sporadic, a result of pituitary insult or developmental 
abnormalities.  5-30% of cases have an affected first-degree relative and are 
genetic (Cogan et al., 1993; Phillips III, 1995).  In addition to GH-1 mutations, 
other mutations that cause GHD have been characterized in a series of genes 
involved in pituitary development and GH-1 expression.  These genes include the 
transcription factors, Pit-1, Prop-1 (Prophet of Pit-1), Hesx-1, Sox-2, Sox-3, Lhx-3 
and Lhx-4 and in the GHR and GHRH-receptor genes (Mullis, 2005; Mullis, 
2007). 
A GHD phenotype can be either isolated (IGHD) or associated with 
combined pituitary hormone deficiency, CPHD (Dattani and Robinson, 2000).  
There are four, well-characterized, distinct familial types of IGHD; IGHD type IA 
and IB, IGHD II and IGHD III, where clinical phenotypes are restricted to the GH 
axis (Mullis, 2005; Phillips III, 1995).  In addition to short stature, IGHD patients 
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exhibit other symptoms including delayed skeletal development (though still in 
proportion to their height), delayed puberty (but normal fertility), truncal obesity, 
delayed secondary dentition, young facial appearance, and occasional fasting 
hypoglycemia (Moseley and Phillips III, 2000).  IGHD IA and IB are inherited in 
an autosomal recessive manner.  IGHD IA is the most severe form of IGHD I with 
gross GH-1 deletions and development of anti-GH antibodies in response to GH 
treatment (Illig, 1970; Phillips III, 1995; Phillips III et al., 1981).  IGHD IB is 
characterized by low but detectable serum GH levels (<2.5ng/ml) and patients 
respond well with immunological tolerance to exogenous GH (Mullis, 2005).  
Mutations causing IGHD IB include missense and splice site mutations in GH-1 
(in intron 4) plus mutations in the GHRH-receptor gene (Moseley and Phillips, 
2000; Mullis, 2005).  IGHD II is an autosomal dominant form of IGHD, which is 
characterized by mutations that disrupt GH-1 splicing and cause skipping of exon 
3.  Three substitution mutations, R183H, P89L and V110F, are also responsible 
for an IGHD II phenotype but do not affect GH-1 splicing (Binder et al., 2001; 
Deladoey et al., 2001; Duquesnoy, 1998).  Rare mutations have also been 
identified in the Hesx-1 (homeobox gene expressed in embryonic stem cells) 
gene that cause IGHD II (Fintini et al., 2006).  Five cases of IGHD II have been 
identified where no mutations have been observed in either GH-1 or Hesx-1, 
suggesting mutations in other genes could also cause IGHD II (Fintini et al., 
2006).  IGHD III is a X-linked, recessive disorder that may involve 
mutations/deletions within the long arm of chromosome X and these might be 
caused by mutations in the Btk (Bruton’s tyrosine kinase) gene (Conley et al., 
 44 
1991; Duriez et al., 1994).  Btk mutatons have been associated with IGHD, 
suggesting that genes critical for GH production exist on the X-chromosome 
(Stewart et al., 1995). 
 
Growth Hormone Splicing 
GH-1 is composed of five exons and four short introns, which can be 
spliced to produce at least five distinct isoforms (Figure 7) (DeNoto et al., 1981).  
Constitutive splicing of GH-1 includes all five exons and these wild-type 
transcripts encode a 22-kDa protein, which is the major, biologically active form 
of GH.  Of the other isoforms, the 20-kDa is the most abundant (5-10% of normal 
GH-1 transcripts) caused by activation of an in-frame cryptic 3’ splice site in exon 
3 (cryptic transcripts) that results in elimination of the first 45 nt of this exon 
(amino acids 32-46) (Cooke et al., 1988; Masuda et al., 1988; Procter et al., 
1998; Stewart et al., 1992; Tsushima et al., 1999).  This isoform is thought to 
retain much of the biological activity of the wild type, 20-kDa protein (Asada et 
al., 2000; Ishikawa et al., 2000; Ishikawa et al., 1999; Masuda et al., 1988).  
Complete skipping of exon 3 (∆3 transcripts) produces a 17.5-kDa protein, 
accounting for 1-5% of pituitary GH-1 transcripts (Lecomte et al., 1987; Procter et 
al., 1998).  This hGH isoform acts in a dominant negative fashion by preventing 
secretion of the wild type, 22-kDa protein.  Transcripts skipping exons 3-4 or 
exons 2-4, encoding 11.3-kDa or 7.4-kDa proteins, respectively, have also been 
identified (Palmetshofer et al., 1995). 
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Figure 7. GH-1 alternative splicing pattern. GH-1 comprises 5 exons and 4 
introns that are constitutively spliced to produce a wild type 22 kDa GH protein.  
Alternative splicing events give rise to other isoforms, the four most common are 
depicted.  The cryptic splice site is denoted by dashed lines. 
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 The 17.5-kDa GH isoform results from aberrant splicing of the GH-1 
transcript and acts in a dominant negative fashion highlighting the absolute 
importance of maintaining splicing fidelity.  The splice sites within introns 2 and 3 
are particularly weak and the cryptic splice site within exon 3 is a stronger splice 
site than the actual 3’ splice site of intron 2.  Accurate splicing of GH-1 transcripts 
requires the concerted effort of three splicing enhancers (ESE 1, ESE 2 and ISE) 
to maintain inclusion of the exon (Figure 8).  Both ESEs are in exon 3; ESE 1 
comprises the first seven nucleotides of the exon and ESE 2 is a 15 nucleotide 
sequence upstream of the cryptic splice site (E3+19-33) (Moseley et al., 2002; 
Ryther et al., 2004; Ryther et al., 2003).  ESE 1 was first identified as a six 
nucleotide motif in a family with IGHD II that had an A→G transition at the fifth 
nucleotide of exon 3 (Moseley et al., 2002).  Subsequent deletion analysis 
extended ESE 1 to include the first seven nucleotides of exon 3, 5’-GAAGAAG-3’ 
(Ryther et al., 2004).   ESE 1 promotes definition of exon 3 by activating the 3’ 
splice site of intron 2 and preventing use of the cryptic splice site (Ryther et al., 
2004; Ryther et al., 2003).  A series of deletions within exon 3 and subsequent 
splicing analyses identified a second enhancer, ESE 2, that also activates exon 3 
inclusion (Ryther et al., 2004).  ISE is a nine nucleotide purine-rich sequence 
within intron 3 (IVS3+26-34), first identified by the presence of two patient 
mutations, IVS3+28 G→A and IVS3∆28-45. (Cogan et al., 1997; Cogan et al., 
1995; McCarthy and Phillips, 1998).  ISE promotes exon 3 definition (Ryther et 
al., 2003). 
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 Patients with mutations that disrupt either the splice sites flanking exon 3 
or any of the enhancer elements exhibit increased skipping of exon 3 and 
therefore suffer from IGHD II due to increased production of the 17.5-kDa isoform  
(Binder and Ranke, 1995; Cogan et al., 1997; Cogan et al., 1995; Fofanova et 
al., 2003; Hayashi et al., 1999a; Kamijo et al., 1999; McCarthy and Phillips III, 
1998; Millar et al., 2003; Missarelli et al., 1997; Moseley et al., 2002; Phillips III 
and Cogan, 1994; Ryther et al., 2003; Takahashi et al., 2002) reviewed in (Mullis, 
2007); Figure 9).  These mutations have different effects upon the extent of exon 
3 skipping.  Those in the splices sites, particularly the 5’ splice site of intron 3, 
usually cause more skipping than mutations that affect enhancers, leading to 
greater production of the 17.5-kDa protein.  Since an increase in the 17.5-kDa 
isoform correlates with an increase in severity of IGHD II symptoms (see below), 
it appears that splice site mutations, rather than enhancer, mutations, trigger 
more severe forms of IGHD II.  Patients with splice site mutations have an earlier 
age of onset and exhibit greater clinical severity.  There is also variation in exon 
3 skipping and disease severity among mutations at the 5’ splice site.  Mutations 
affecting the first two nucleotides (IVS3 +1/+2) always cause exon 3 skipping 
whereas transcripts with mutations at positions +5/+6 (IVS3 +5/+6) allow minor 
levels of normal splicing.  This observation is explained by the conserved GU 
dinucleotide at the 5’ end of the intron, which pairs with U1 snRNA.  Disruption of 
base-pairing between the mRNA and the snRNA inhibits spliceosome assembly.  
For mutations at positions at +5/+6, skipping is not as extreme since these 
nucleotides are not as highly conserved.   
 49 
 
Mouse Model of Isolated Growth Hormone Deficiency type II 
 How the 17.5 kDa isoform acts in a dominant negative fashion is only 
partially understood.  A transgenic mouse model of IGHD II has been created 
that expresses a human mutant GH-1 transcript expressed from a cosmid 
containing the entire GH-1 LCR, including upstream DNA elements required for 
somatotroph-specific expression (McGuinness et al., 2003; Ryther et al., 2003).  
The transgene contains a G to A transition at the 5’ splice site of intron 3 (IVS3+1 
G→A) that leads to exclusive production of the 17.5-kDa isoform (McGuinness et 
al., 2003) and exerts a dominant negative effect on wild type mouse GH (mGH).  
This inhibition is dose-dependent; high copy transgenic mice exhibit far more 
extreme phenotypes than those with low copy numbers (McGuinness et al., 
2003).  This correlates with the severity of symptoms observed in IGHD II 
patients with regard to the amount of exon 3 skipping (Mullis et al., 2005).  Even 
in the presence of two wild type mGH alleles, high copy transgenic mice exhibit 
severe IGHD II with concomitant reduced weight, severely reduced pituitary GH 
content, and progressive anterior pituitary hypoplasia (McGuinness et al., 2003; 
Ryther et al., 2003; Shariat et al., 2007).  Overproduction of the 17.5-kDa isoform 
triggers not only somatotroph death but also destruction of neighboring cells by 
macrophage invasion, leading to severe hypoplasia and additional anterior 
pituitary hormone deficiencies (McGuinness et al., 2003).  This is evident in 
electron micrographs where pituitaries from IGHD II mice show a lack of DCSVs 
and extreme vacuolation (McGuinness et al., 2003; Shariat et al., 2007).  
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Patients with severe IGHD II often develop additional pituitary hormone 
deficiencies, particularly ACTH and TSH, which require additional treatment 
(Mullis et al., 2005).  The IGHD II mouse model showed deficiencies in PRL and 
TSH at weaning, worsening by 8-10 weeks of age compared to non-transgenic 
littermates.  At the later time point, a loss of LH was also evident (McGuinness et 
al., 2003).  Variability in the age of onset and severity of IGHD II among patients 
is thought to be due to the amount of the 17.5-kDa isoform relative to the wild 
type, 22-kDa protein and occurs from splicing mutations that generate differential 
exon 3 skipping (Mullis, 2007; Mullis et al., 2005).  This result suggests a 
threshold and dose-dependence of the amount of the 17.5-kDa isoform above 
which somototroph death and pituitary defects are triggered (McGuinness et al., 
2003).   
 Exclusion of exon 3 results in loss of amino acids 32-71 in the 17.5-kDa 
isoform.  This deletion corresponds to the entire loop region between helices 1 
and 2 (Ultsch et al., 1994).  The deletion also disrupts an internal disulfide bridge 
by elimination of Cys53, leaving an unpaired Cys165.  It has been assumed that 
the 17.5-kDa is strongly misfolded, though mechanisms of how it functions in a 
dominant negative manner are only just being elucidated.  It is not likely that 
disruption of intra- or intermolecular disulphide bridges is responsible since a 
compensatory mutation of the unpaired Cys165 still results in a mutant GH with a 
dominant negative effect (Lee et al., 2000) and another mutation, R77C, which 
disrupts a disulfide bridge does not have a dominant negative effect on wild-type 
GH (Takahashi et al., 1996).  The dominant negative effect upon the wild-type 
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GH is also seen with missense mutations that do not affect GH-1 splicing (Binder 
et al., 2001; Deladoey et al., 2001; Duquesnoy, 1998).  One current model 
proposes that as the 17.5-kDa and wild type GH isoforms progress through the 
secretory pathway, they form heterodimers that do not efficiently condense in the 
trans-Golgi, preventing formation of DCSVs (McGuinness et al., 2003) (Figure 
9b).  It is postulated that these heterodimers accumulate in the Golgi and then 
back up into the ER, triggering an unfolded protein response (Graves et al., 
2001).  When proteins misfold, they are often retained in the endoplasmic 
reticulum (ER) and targeted for degradation (Ellgaard et al., 1999).  Cells exhibit 
a variety of responses to the accumulation of misfolded protein in the ER.  This 
includes the unfolded protein response, which involves transcriptional activation 
of genes encoding a wide range of proteins necessary for protein folding and 
secretion (Bernales et al., 2006; Chapman et al., 1998).  The model above 
supports findings in which the 17.5-kDa isoform has been expressed in various 
cell lines.  In transient transfections in neuorendocrine cell lines, the 17.5-kDa 
isoform decreased intracellular and secreted wild-type forms of GH (Graves et 
al., 2001; Hayashi et al., 1999b; Lee et al., 2000; McGuinness et al., 2003). The 
mutant GH isoform had no specific dominant negative effect upon wild-type GH 
secretion in non-neuroendocrine cell lines, though in COS7 cells, the 17.5-kDa 
isoform disrupted trafficking of both plasma membrane and secretory proteins 
(Graves et al., 2001; Lee et al., 2000).  Confocal studies showed co-localization 
of the 17.5-kDa isoform with components of the ER, Golgi and also, albeit 
minimally compared to wild-type, with secretory granules (Salemi et al., 2006).  
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Recent data in stable somatotroph cell lines expressing both wild type and 
∆3 transcripts shows that the 17.5-kDa isoform is irregularly folded and degraded 
in a proteosome-dependent manner (Kannenberg et al., 2007).  Once the 
degradative capacity of the proteosome is exceeded, toxic GH aggregates form 
in the cytosol, ER and Golgi (McGuinness et al., 2003).  In the mouse model of 
IGHD II, an increase in GHRH and a decrease in somatostatin were observed, 
causing increased mutant GH-1 expression and further accelerating the toxic 
effects of the 17.5-kDa protein (McGuinness et al., 2003).  However, this does 
not seem to be a problem in patients with IGHD II (Mullis, 2005).  
 
RNA Interference as a Therapy for IGHD II 
Transcripts lacking exon 3 possess a unique sequence at the boundary of 
exon 2 and exon 4 that is not present in any other spliced GH-1 products.  As a 
result, the ∆3 transcript is an ideal target for knock down by RNAi using siRNAs 
complementary to this unique sequence (Ryther et al., 2004).  As discussed 
above, while treatment with recombinant GH (rGH) rescues short stature, IGHD II 
patients often develop additional hormonal deficiencies.  Specifically targeting 
transcripts that encode the 17.5-kDa isoform, a direct cause of IGHD II, is 
extremely advantageous and highlights a potentially ideal way to treat patients 
diagnosed with IGHD II caused by mutations that disrupt GH-1 splicing. 
The following work illustrates that RNAi can be used to effectively treat 
IGHD II in a mouse model of IGHD II.  We developed transgenic mice expressing 
an shRNA complimentary to the ∆3 transcript (shRNA-17.5).  These mice were 
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bred with IGHD II mice, and the resulting progeny were ‘rescued,’ meaning they 
did not exhibit disease symptoms. 
We also identify and characterize a new mutation in GH-1 in a family 
suffering with IGHD II.  The mutation occurs at the first base of exon 3, 
corresponding to the 3’ splice site and to ESE 1.  Disruption of these splicing 
elements promotes skipping of exon 3 and an increase in the 17.5-kDa isoform.   
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Summary 
Context: Genetic mutations that lead to amino acid changes are most commonly 
believed to be due to altered protein function but such changes can also exert 
their effects at earlier stages by affecting splicing.     
Objective: Exon 3 of the human growth hormone gene (GH-1) contains two 
splicing enhancers that prevent exon skipping.  We made use of a novel patient 
mutation that causes Isolated GH Deficiency type II to determine whether the 
overall defect was due to a missense mutation, a splice site mutation, or a 
splicing enhancer mutation. 
Design, Setting and Patients:  A heterozygous guanine to adenine transition at 
the first nucleotide of exon 3 (E3 +1 G→A) in GH-1 was identified in a family 
presenting with IGHD II.  Although this mutation encodes an amino acid 
substitution, GH-E32K, it also resides within a splicing enhancer and is part of 
the 3’ splice site of exon 3. 
Interventions and Results:  Interestingly, the E3 +1 G→A causes an increase 
in skipping of exon 3 transcripts by disrupting an exon splicing enhancer and 
weakening the 3’ splice site. Thus, exon skipping due to production of a dominant 
negative 17.5-kDa isoform forms the basis of disease for this mutation.  
Transcripts encoding the 17.5-kDa isoform can be targeted for specific 
degradation using RNA interference in patient derived lymphoblastoid cell lines.   
Conclusion:  The predicted GH-E32K amino acid substitution is not responsible 
for GHD.  Instead, the mutation causes aberrant splicing due to disruption of a 
splicing enhancer within exon 3 coupled to a weakening of the 3’ splice site.  The 
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resulting increase in the 17.5-kDa isoform causes IGHD II.  This study illustrates 
that RNA serves as more than just a code for protein production and that it is 
important to look beyond the protein sequence when assaying genetic mutations. 
 
Introduction 
The human GH gene, GH-1, comprises five exons that are constitutively 
spliced to produce the full-length, 22-kDa protein.  The majority of circulating GH 
is translated from mRNAs containing all 5 exons but aberrant splicing of wild type 
transcripts gives rise to at least 5 other smaller isoforms, the most abundant of 
which are a 20-kDa isoform and a 17.5-kDa isoform (Procter et al., 1998) (Figure 
7).  The 20-kDa protein lacks amino acids 32-46 due to activation of an in-frame 
cryptic splice site within exon 3 but apparently retains full functionality (Stewart et 
al., 1992).  Complete skipping of exon 3 generates the 17.5-kDa isoform that acts 
in a dominant negative manner (Figure 9).  Even in normal individuals, RNAs 
encoding the 20-kDa and 17.5-kDa isoforms account for approximately 5-10% 
and 1-5% of GH-1 transcripts, respectively (Procter et al., 1998).   
The 17.5-kDa isoform exerts a dominant negative effect by preventing 
secretion of wild type GH in both tissue culture cells and in transgenic mice 
(Hayashi et al., 1999b; Lee et al., 2000; McGuinness et al., 2003; Shariat et al., 
2007).  Patients with inherited mutations that increase the levels of the 17.5-kDa  
isoform exhibit Isolated GH Deficiency type II (IGHD II), an autosomal dominant 
form of GHD.  Common characteristics of IGHD II include short stature due to 
impaired bone elongation, delayed puberty, and, in severe cases, anterior 
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pituitary hypoplasia with concomitant disruption of the anterior pituitary hormone 
axis. 
Splicing is catalyzed by a macromolecular complex termed the 
spliceosome whose RNA and protein moieties recognized conserved sequences 
in the mRNA, namely the 5’ splice site, the branch point/polypyrimidine tract, and 
the 3’ splice site (Moore et al., 1993) (Figure 1).  In higher eukaryotes these 
splice sites are poorly conserved and this lack of sequence conservation has at 
least two consequences.  First, exons and introns must be properly recognized to 
maintain splicing fidelity even when the flanking sites are weak, a daunting task 
given that exons are typically small and sequences resembling bona fide splice 
sites can often be found within the sea of RNA that constitutes introns (Black, 
1995; Smith and Valcarcel, 2000).  Second, regulated splicing is common, 
involving differential recognition of splice sites, alternative splicing, and the 
production of an incredibly diverse proteome from a relatively small genome 
(Modrek and Lee, 2002; Smith and Valcarcel, 2000).  For both splicing fidelity 
and alternative splicing, additional cis-acting regulatory elements have been 
identified that aid identification of the correct splice sites.  The two best 
characterized elements are referred to as splicing enhancers and silencers 
(Blencowe, 2000; Solis et al., 2008; Weighardt et al., 1996).  Splicing enhancers 
are typically purine-rich and aid exon and intron definition (Blencowe, 2000; 
Tacke and Manley, 1999).   
  The splice sites surrounding exon 3 in GH-1 are relatively weak and 
require the concerted effort of three splicing enhancers to ensure inclusion 
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(Ryther et al., 2004).  Two of these enhancers reside within exon 3 (Exonic 
Splicing Enhancers (ESEs) 1 and 2; whereas the third is found in the 
downstream intron (ISE) (Figure 8).  ESE 1 comprises the first seven bases of 
exon 3 and is required for both proper recognition of the upstream 3’ splice site 
and suppression of the downstream cryptic splice site (Ryther et al., 2003).  
Suppression of the cryptic splice site is necessary because it is a stronger 3’ 
splice site sequence than the wild type 3’ splice site (scores of 91 and 85 
respectively, calculated according to Shapiro and Senepathy, 1987; 
http://genet.sickkids.on.ca/~ali/splicesitescore.html).  Molecular analyses of ESE 
2 and ISE have shown that both function to ensure proper exon 3 definition to 
avoid skipping.  From an evolutionary perspective, it is interesting that the GH-1 
gene requires the action of multiple enhancer elements to ensure splicing fidelity.  
Disruption of any of these elements leads to the production of aberrant GH, 
mostly involving skipping of all or portions of exon 3.   
Here, we examine the sequence requirements to maintain accurate 
splicing of GH-1 transcripts by characterizing a heterozygous mutation 
discovered in a family presenting with IGHD II.  This mutation is a guanine to 
adenine transition at the first base of exon 3 (E3+1 GA) (Figure 10).  Our 
analysis shows that this transition mediates its effects in two ways; by disrupting 
ESE 1 and by weakening the 3’ splice site consensus sequence.  While GH is 
primarily expressed in somatotroph cells in the anterior pituitary, we also detect 
aberrantly spliced transcripts in patient-derived lymphoblastoid cell lines (LCLs) 
providing a unique tool to molecularly characterize the effects of specific 
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mutations in heterozygous settings.  Small interfering RNAs (siRNAs) can be 
introduced into these LCLs to specifically degrade transcripts encoding the 17.5-
kDa isoform. 
 
Subjects and Methods 
 
Subjects 
We studied DNA from members of a Caucasian family presenting with 
IGHD II, inherited in an autosomal dominant manner whose pedigree is shown in 
Figure 10a.  Clinical tests and pedigree analysis confirmed autosomal IGHD II.  
Sequencing of DNA from family members identified a heterozygous E3+1 G→A 
transition in the GH-1 gene in affected IGHD II individuals that is predicted to 
encode an E32K substitution (Figure 10b).  Patient I-I was examined and 
diagnosed at age 2 years 5 months with IGHD II based on short stature, low GH 
levels, both resting and following stimulation.  The clinical data are shown in 
Table 2.  A cranial MRI done prior to treatment showed a hypoplastic anterior 
pituitary.  He was started on subcutaneous GH replacement therapy (Humatrope) 
at two years and six months and showed a good response to treatment within the 
first four months.  Following therapy, slight scoliosis of the spine and increased 
truncal adiposity exhibited before treatment have been reduced.  Currently, at 
age five years and three months, the patient is at the 25th percentile for height. 
 
Cell Culture and In Vivo Splicing Analyses 
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 Blood samples were obtained from the subject and affected members of  
his family after obtaining consent.  Genomic DNA was isolated from total blood 
and the GH-1 gene sequenced (Cogan et al., 2006).  The primers used for 
amplification and subsequent sequencing of GH-1 were: 5’-
CCAGCAATGCTCAGGGAAAG-3’, 5’-
TGTCCCACCGGTTGGGCATGGCAGGTAGCC-3’ and 5’-
CTGGGAAATAAGAGGAGGAGAC-3’.  LCLs were isolated and transformed as 
previously described (Oh et al., 2003) and were maintained in RPMI 
supplemented with 20% FBS.  Total RNA was isolated from 2x106 cells using 
RNeasy (Qiagen) and 3µg was used for cDNA synthesis using SuperScript III 
(Invitrogen) with oligo d(T) primers.  cDNA products were amplified using 32P-
labeled GH-1-specific primers (Ryther et al., 2003) followed by separation on 6% 
polyacrylamide gels and exposure to phosphorimager analysis.  Amplifying 
spliced products with the same primers allowed accurate quantitation within the 
same lane, obviating the need for a loading control.  Results are thus shown as a 
ratio of the three products derived from a single lane. 
Mutant constructs were generated from wild type GH-1 in pXGH5 by 
reverse PCR (Coolidge and Patton, 1995) using mismatch primers followed by 
sequence verification.  Rat somatotroph GH3 cells were grown in DMEM with 
10% FBS and transfected with 1µg of wild type or mutant constructs using Mirus 
LT1 reagent (Mirus Bio).  Total RNA was isolated after 48 hours using TRI 
reagent (MRC) and cDNA was synthesized using a GH-1-specific RT primer with  
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Figure 10. Identification of a heterozygous mutation in GH-1 that causes 
IGHD II. (A) Genetic pedigree showing inheritance of a mutation at the first 
position of exon 3 (E3 +1) in the human growth hormone gene (GH-1).  The 
genotype for the two alleles at this position is indicated as either homozygous 
(G/G) or heterozygous (G/A).  Lymphoblastoid cell lines were generated from 
patients I-I and I-II. , affected males; , affected females;  unaffected males; 
 unaffected females. (B) GH-1 sequencing data from an individual containing a 
heterozygous G→A transition at the first base of exon 3.  Blue asterisk denotes 
the IVS3+1 G→A mutation used in Figure 11. 
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M-MLV reverse transcriptase (Promega) as previously described (Ryther et al., 
2004).  Splicing patterns were determined by RT-PCR as above. 
 
In Vitro Splicing Analysis 
Wild-type or mutant ESE1 sequences were cloned into exon 2 of an 
enhancer dependent splicing construct derived from the Drosophila 
melanogaster doublesex gene (DSX; a kind gift from Dr. B. Graveley) by reverse 
PCR (Coolidge and Patton, 1995).  Primers with either adenine, thymine or 
cytosine in place of the first base of ESE1 were used to generate the mutant 
ESE1 DSX constructs.  The DSX constructs were linearized with MluI and in vitro 
transcribed in the presence of α-32P-ATP and a cap analogue with T7 RNA 
Polymerase (NEB).  Labeled transcripts were incubated for 2 hours at 30°C in 
60% HeLa nuclear extract.  Splicing products were separated on 8% denaturing 
polyacrylamide gels and exposed to phosphorimager analysis. 
 
Electroporation of siRNAs 
150,000 LCLs were centrifuged at 2,000xg for five minutes, resuspended 
in 75µl siPORT electroporation buffer (Ambion) and electroporated with 5µg of 
siRNA-17.5 or siRNA-GFP (Dharmacon) in a 1mm cuvette under the following 
conditions: single square wave pulse, 325V, 13ms.  After electroporation, cells 
were incubated for 10 minutes at 37°C before being plated in pre-warmed media.  
After 48 hours, all cells were re-electroporated under the same conditions.  For  
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Table 2. Clinical characteristics of subject I-II aBefore therapy; bAfter therapy; 
cHighest GH peak after stimulation; IGF BP-III, IGF-1 binding protein; TSH, 
thyroid stimulating hormone. 
 
 
 
 I-I 
Sex M 
Age (yrs) 2 5/12a 4 9/12b 
Height (cm) 75.7a 104b 
SD score -4.62a  -0.95b 
Weight (kg) 9.5kga 16.6b 
BMI (kg/m2) 15.7a 15.32b 
GH ng/ml 0.91 
(0.43-2.4) 
Provocation tests 
(GH ng/ml) 
Chlonidine: 1.12c 
Arginine: 1.14c 
IGF-1 ng/ml 28.8 
(51-303) 
IGF BP-III (ug/ml) 1.2 
(0.8-3.9) 
TSH (ulU/ml) 1.18 
(0.36-7.6) 
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mock electroporations, LCLs were electroporated in the absence of siRNAs.  
Total RNA was harvested after a further 48 hours. 
 
Results 
GH-1 sequences from affected individuals showed a heterozygous single 
guanine to adenine transition in the first nucleotide of exon 3 (E3+1 GA) (Figure 
10b).  This change results in a glutamic acid to lysine (E32K) change in the 
amino acid sequence of GH for all mutant transcripts that include exon 3.  
Despite the missense mutation, we hypothesized that the E3+1 GA mutation 
causes disease through a different mechanism for two reasons.  First, affected 
individuals are heterozygous for the mutation and haploinsufficiency does not 
typically cause IGHD II.  Second, the majority of mutations that cause IGHD II do 
so by inducing skipping of exon 3 to produce the dominant negative 17.5-kDa 
isoform.  There are at least two possible ways splicing could be affected.  First, 
the mutation weakens the 3’ splice site of exon 3 to AG|A (Figure 10b).  The 
consensus sequence for 3’ splice sites is AG|G where the last guanine is the 
preferred nucleotide as the first base of exons.  For the major class of introns, the 
AG dinucleotide at the end of introns is absolutely conserved whereas the G at 
the first position of exons is found in only ~52.5% of cases (A is 22.5%; C and U 
both 12.5%) (Burge et al., 1999).  A second, but not mutually exclusive 
possibility, is that the E3+1 GA mutation disrupts ESE 1 (Figure 10b).   
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A Weak 3’ Splice Site Increases Exon Skipping 
To determine if the E3+1 GA mutation actually alters splicing, we 
transfected rat somatotroph (GH3) cells with a vector expressing wild type GH or 
a construct containing the E3+1 GA mutation.  To analyze the effects of base 
changes in the first nucleotide of exon 3, we also created constructs containing 
E3+1 GT and E3+1 GC.  The E3+1 GT mutation has previously been 
reported to cause IGHD II (Takahashi et al., 2002).  Cells were transfected with 
these constructs, RNA was isolated 48 hours later, and splicing patterns were 
analyzed by RT-PCR.  As expected, the wild-type sequence resulted in 
predominant production of transcripts encoding the 22-kDa isoform with only 
~6% exon 3 skipping (Figure 11a).  All three base changes resulted in an 
increase in exon 3 skipping (∆3 transcripts) with the E3+1 GA mutation causing 
less skipping (39%) than either of the other mutants, GT or GC, 78% and 
65%, respectively (Figure 11a).  The E3+1 GT mutant introduces an in-frame 
premature termination codon (GAA→UAA; PTC) and, consistent with nonsense-
mediated mRNA decay (NMD), no wild-type transcripts were detectable when 
this construct was expressed (Figure 11a, lane 2).  The E3+1 GC causes a 
glutamic acid to glutamine amino acid change upon inclusion of exon 3 which 
should not cause NMD.  Nevertheless, this mutation led to only minimal 
production of correctly spliced transcripts and significantly increased levels of 
transcripts encoding the 17.5-kDa isoform.  Comparing the wild type, A, and C 
constructs, it is apparent that there is a preference for a G at position 1 of exon 3 
followed by A and then C.  The effect of a T cannot be determined under these  
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Figure 11.  E3+1 G→A causes an increase in skipping of exon 3. (A) Rat 
GH3 cells were transfected with human GH-1 E3+1 constructs in which the 
nucleotide at the first position of exon 3 is as indicated above.  The wild type 
sequence contains a G.  RNA was isolated and RT/PCR was performed using 
GH-1-specific primers in exon 2 and exon 5.  Bands corresponding to the 
different spliced products are indicated to the left and the percentages of these 
products are listed below based on ratios within each lane from three 
independent experiments.  (B) Patient derived lymphoblastoid cell lines were 
generated from patients as described in Fig. 1.  GH-1 splicing patterns were 
determined by isolation of RNA from individual cell lines and RT/PCR as above.  
IVS3+1 G→A was derived from a patient heterozygous for a mutation in the first 
base of intron 3.  
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conditions due to NMD.  Despite that, the results are consistent with the percent 
that each of these bases is found in consensus 3’ splice sites. 
 
Splicing Analysis in Patient-Derived Lymphoblastoid Cell Lines 
The experiments shown in Figure 11a were performed in cultured GH3 
cells, which mimic a homozygous mutant background.  To confirm that the 
splicing patterns observed under these conditions accurately reflect splicing 
patterns that occur in heterozygous, patient derived cell lines, we created LCLs 
from both affected and unaffected individuals.  Although GH is normally 
expressed in anterior pituitary somatotrophs, we sought to determine whether we 
could detect limited amounts of GH-1 transcripts in LCLs derived from IGHD II 
patients rather than after transfection into heterologous GH3 cells.  RNA was 
isolated from these cell lines and endogenous GH-1 splicing patterns were 
examined by RT-PCR using specific primers.  Interestingly, as shown in Figure 
11b, we could readily detect GH-1 transcripts in LCLs derived from both normal 
and GH-deficient patients.  The overall pattern of RT-PCR products is slightly 
different from that observed in transfected GH3 cells due to some additional 
unknown faint bands migrating close to the band corresponding to transcripts 
encoding the 20-kDa isoform.  While this may slightly alter the percentage of 
each transcript, it is clear that there is a dramatic increase in transcripts encoding 
the 17.5-kDa isoform in GH-deficient LCLs.  When we compared the levels of ∆3 
transcripts in three individuals with GH deficiency, the levels of the dominant 
negative 17.5-kDa isoform correlated with disease severity.  For the two 
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individuals with heterozygous E3+1 GA mutations, the levels of ∆3 transcripts 
were lower (Figure 11b, lanes 3 and 4) compared to an individual containing a 
mutation at the 5’ splice site of intron 3 (IVS3+1 G→A), in agreement with clinical 
observations for both types of mutations (Binder et al., 2001; Millar et al., 2003; 
Moseley et al., 2002; Mullis et al., 2005).    
 
Disruption of ESE 1 and Exon 3 Skipping 
While the 3’ splice site consensus sequence is altered in patients 
containing the E3+1 GA mutation, there are many functional 3’ splice sites that 
contain an adenine as the first base of the exon.  Thus, as far as IGHD II is 
concerned, this mutation may be deleterious because it not only makes the 3’ 
splice site weaker, but it also alters ESE 1.  To determine whether the E3+1 GA 
mutation causes skipping of exon 3 due to disruption of ESE1, we created a 
series of constructs designed to test enhancer activity.  Single copies of wild type 
and mutant ESE1 were cloned into a construct derived from the D. melanogaster 
doublesex (DSX) gene where splicing is enhancer dependent (Figure 12a) 
(Caputi et al., 2002; Graveley et al., 1998; Tian and Maniatis, 1992; Tian and 
Maniatis, 1994).  RNA transcripts from these constructs were produced by in vitro 
transcription and then spliced in HeLa cell nuclear extracts.   Previous work has 
shown that multimers of small, purine-rich sequences can act as enhancer 
elements in this setting (Graveley et al., 1998).  Therefore a single GA mutation 
at the start of ESE 1 might not alter enhancer activity if inserted as a single 
change amidst a multimer of ESE1 elements.  As a result, we chose to insert  
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Figure 12.  E3+1 G→A disrupts enhancer function. (A) Schematic of the 
doublesex (DSX) minigene construct showing two exons (boxes) and an intron 
(line).  Wild type and mutant ESE1 sequences were cloned into exon 2 (striped 
box).  The first base of ESE1 (red, bold) was mutated to A, T or C.  (B) RNAs 
derived from the constructs above were prepared by in vitro transcription 
followed by splicing in HeLa nuclear extracts.  Splicing reactions were subjected 
to denaturing polyacrylamide electrophoresis with the precursor and products as 
depicted.  *Activation of splicing by wild-type ESE1 is significantly greater than 
the other four constructs (p-value < 0.0001; n = six independent experiments). 
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only a single enhancer element even though splicing activation was expected to 
be less than robust.  Nevertheless, we were able to detect splicing activity and 
therefore enhancer activity upon insertion of a single wild type ESE 1 (Figure 
12b).  In contrast, all three mutant ESE 1 constructs (DSX-ESE1-A, DSX-ESE1-T 
and DSX-ESE1-C) were unable to rescue splicing.  This suggests that altering 
the first base of ESE 1 destroys its ability to function as an enhancer.  Thus, the 
E3+1 GA mutation causes aberrant skipping of exon 3 by both altering the 3’ 
splice site and by disrupting ESE1.  
 
RNAi in Lymphoblastoid Cell Lines 
Transcripts lacking exon 3 possess a unique sequence at the boundary of 
exon 2 and exon 4 that is not present in any other spliced GH-1 products.  As a 
result, the dominant negative ∆3 transcripts present an ideal target for knock 
down by RNAi using siRNAs complementary to this unique sequence (Figure 
13a).  In chapter III we show that RNAi can be used successfully in vivo to 
rescue IGHD II phenotypes in a mouse model (Shariat et al., 2007).  To see if we 
could reduce levels of the ∆3 transcript in heterozygous patient-derived cells, we 
electroporated LCLs with siRNAs directed against the unique exon 2-4 junction 
found only in transcripts encoding the 17.5-kDa isoform (siRNA-17.5).  RT-PCR 
analysis showed specific knock down of mutant transcripts in three patient lines 
whereas an siRNA control (siRNA-GFP) had no effect (Figure 13b).  We 
observed no apparent defects in the rates of cell growth or other obvious 
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phenotypes in the siRNA treated cell lines suggesting that off target effects are 
minimal (Jackson et al., 2006b). This is consistent with similar findings using 
RNAi to rescue a murine model of IGHD II supporting the idea that RNAi could 
be useful to treat IGHD II in humans (Shariat et al., 2007).  
 
Discussion 
 The GH-1 gene contains multiple weak splice sites and even in normal 
individuals, exhibits low levels of aberrant splicing resulting in the skipping of 
different exons (Procter et al., 1998).  To maintain fidelity, multiple cis-acting 
regulatory enhancers have been identified (Ryther et al., 2004).  The great 
majority of mutations in GH-1 that cause IGHD II occur in and around exon 3 and 
cause skipping of this exon (Mullis, 2007).  These mutations include splice site 
mutations as well as disruption of splicing enhancer elements that are necessary 
to promote constitutive splicing.  In this study, we have identified and 
characterized a new mutation, E3+1 GA, which causes IGHD II due to 
increased exon 3 skipping.  Another GH-1 missense mutation, E32A, was 
recently characterized and also shown to increase exon 3 skipping due to 
disruption of ESE 1 due to an A→C transversion (Petkovic et al., 2007).  Since 
this mutation occurs at the second nucleotide of exon 3, it would not be expected 
to affect the 3’ splice site. 
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Figure 13.  Specific targeting of ∆3 transcripts in patient lymphoblast cell 
lines by RNAi.  (A) siRNA-17.5 is complimentary to the unique exon 2-exon 4 
junction in ∆3 transcripts that enode the 17.5-kDa isoform.  (B) Lymphoblastoid 
cell lines from affected and unaffected individuals as in Figures 10 and 11 were 
electroporated with siRNA-17.5, siRNA-GFP or mock electroporated.  Total RNA 
was isolated and spliced products amplified using GH-1-specific primers.  The 
percentages of ∆3 transcripts are shown below and represent three independent 
experiments. 
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Exon 3 Skipping and Disease Severity 
The 17.5-kDa isoform represents 1–5% of wild type GH-1 transcripts even 
in normal human pituitaries (Procter et al., 1998).  Variability in the age of onset 
and severity of IGHD II among patients is thought to be due to increasing 
amounts of the 17.5-kDa isoform relative to the full length, 22-kDa protein 
(Hayashi et al., 1999b; McGuinness et al., 2003; Millar et al., 2003).  Patients 
with IGHD II caused by mutations in either of the first two bases of intron 3 (IVS3 
+1/+2) have a more severe phenotype with earlier onset than those with 
mutations within ESE1 due to increased production of the 17.5-kDa isoform.  We 
show here that this difference in expression is observed in RNA obtained from 
patient derived LCLs (Figure 11b).  IVS3 +1/+2 corresponds to the conserved GU 
dinucleotide at the 5’ splice site that pairs with U1 snRNP binding in the initial 
stages of spliceosome assembly and exon definition.  In this study, we show that 
patients with the E3+1 GA mutation do not exhibit as extreme a phenotype as 
patients with mutations at IVS3 +1/+2, most likely due to reduced exon 3 skipping 
and therefore less production of the dominant negative 17.5-kDa isoform.  These 
phenotypic differences may reflect a threshold and dose dependency of the 
amount of 17.5-kDa isoform above which pituitary defects are triggered (Mullis et 
al., 2005).  In transgenic mouse models of IGHD II, lines expressing high copy 
numbers of human GH-1 alleles containing mutations that result in exclusive 
exon 3 skipping have a more severe phenotype with much reduced growth and 
severe anterior pituitary hypoplasia than mice with lower copy numbers 
(McGuinness et al., 2003; Shariat et al., 2007). 
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ESE1 ensures proper exon 3 definition by activating the 3’ splice site in 
intron 2 while concurrently preventing activation of the cryptic splice site in exon 
3 (Ryther et al., 2003).  For ESE1 mutations, the effects of the GA and GT 
mutations correlate with the severity of IGHD II.  Both mutations cause an 
increase in ∆3 transcripts encoding the dominant negative 17.5-kDa isoform.  
The E3+1 GT mutation produces a PTC that invokes NMD such that any 
transcripts containing the PTC are destroyed so the ratio of spliced products is 
biased toward ∆3 transcripts that lack PTCs.  In contrast, readily detectable 
levels of completely spliced products are detectable with the E3+1 GA 
mutation.  Nevertheless, for both mutations and indeed for the future discovery of 
the E3+1 GC mutation, disease severity will correlate with the levels of exon 
skipping.   
 
Code Within a Code Within a Code  
The experiments shown here provide an excellent illustration of the 
information contained within RNA.  Prior to the realization of the multiple effects 
that mutations can have on RNA processing, it is likely that the effect of the E3+1 
GA mutation would be assumed solely due to the E32K missense mutation that 
is expected to accompany this change.  However, since the mutation alters the 
first base of exon 3 and the first base of ESE 1, its effects, especially related to 
IGHD II, are due to aberrant splicing rather than production of a missense form of 
hGH.  The position of the E3+1 GA creates a change in the 3’ splice site from 
the favored guanine residue.  The initial stages of spliceosome assembly involve 
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the binding of the small subunit of U2 Auxiliary Factor (U2AF35) to the 3’ splice 
site with a preference for G at the first base of the exon (Merendino et al., 1999; 
Wu et al., 1999; Zorio and Blumenthal, 1999).  Even though all four bases can 
function as the first base of exons, the preference for guanine by U2AF35 
weakens sites that contain other nucleotides.  For GH-1, any such weakening is 
further compounded by the fact that ESE 1 begins with the first base of exon 3 so 
that the E3+1 GA mutation creates double indemnity.  For IGHD II, production 
of the dominant negative 17.5-kDa isoform is the key so whether the E32K 
missense mutation actually affects GH function is not known nor particularly 
relevant.  However, for other mutations, should the change affect protein 
production, triple indemnity could ensue for a given mutation.  A pertinent 
example is that of germline mutations in the human breast cancer susceptibility 
gene, Brca-1, which are responsible for approximately half of all familial 
hereditary breast cancer cases and have been shown to confer increased risk of 
ovarian, colon or prostate cancer (Nathanson et al., 2001).  Some mutations in 
Brca-1 that were initially annotated as missense mutations were later shown to 
cause aberrant splicing instead (Yang et al., 2003). 
 
Potential Therapeutic Role of RNAi in IGHD II  
 Current treatment for IGHD II involves subcutaneous injections of 
recombinant GH (rGH) (Drake et al., 2001).  While this enables patients to attain 
near normal stature, it does not replicate the normal, pulsatile pattern of GH 
secretion nor does it prevent anterior pituitary hypoplasia, which can lead to pan-
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pituitary defects (McGuinness et al., 2003; Mullis et al., 2005; Romijn et al., 
2003).  In addition, there are side affects associated with rGH therapy (Monson, 
2003).  RNAi provides a potential, attractive therapeutic strategy to specifically 
target transcripts encoding the 17.5-kDa isoform for degradation (Ryther et al., 
2004; Shariat et al., 2007).  While we have shown that genetic delivery of 
shRNAs can rescue a mouse model of IGHD II, we have not attempted to use 
RNAi to target GH-1 transcripts in human cells.  Here, we have delivered siRNAs 
directly to patient-derived LCLs and shown specific decreases in ∆3 transcript 
levels.  Fortunately, no observable phenotypic effects attributable to potential off 
target effects were observed suggesting that RNAi might be a viable therapeutic 
strategy for IGHD II.  
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Abstract 
Splicing mutations in the human growth hormone (hGH) gene (GH-1) that 
cause skipping of exon 3 result in a form of GH deficiency termed Isolated 
Growth Hormone Deficiency type II (IGHD II) (Figure 9).  The GH-1 gene 
contains 5 exons; constitutive splicing produces the wild type 22-kDa hormone 
while skipping of exon 3 results in transcripts encoding a 17.5-kDa isoform that 
acts as a dominant negative to block secretion of the wild type hormone.  
Common characteristics of IGHD II include short stature due to impaired bone 
elongation growth and, in severe cases, anterior pituitary hypoplasia.  Typically, 
IGHD II is treated by subcutaneous delivery of hGH which can rescue stature 
but, unfortunately, does not inhibit pituitary hypoplasia.  Direct destruction of 
transcripts encoding the dominant negative 17.5-kDa isoform should both rescue 
stature and prevent hypoplasia.  Here, we have used delivery of short hairpin 
RNAs (shRNAs) to rescue a murine model of IGHD II by specifically targeting 
transcripts encoding the 17.5-kDa isoform using RNA interference.  To our 
knowledge, this is the first example where an shRNA has been expressed to 
specifically degrade an incorrectly spliced transcript and rescue a dominant 
negative disease phenotype in vivo. 
 
Introduction 
 The great majority of mutations that lead to IGHD II occur in and around 
exon 3 and lead to aberrant splicing (Mullis, 2007).  These mutations include 
splice site mutations as well as disruption of splicing enhancer elements that are 
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necessary to promote constitutive splicing (Figure 8) (Ryther et al., 2004).  GH-1 
comprises five exons that are constitutively spliced to encode the wild type 22-
kDa isoform.  Transcripts lacking exon 3 encode a 17.5-kDa dominant negative 
isoform that prevents secretion of wild type protein from somatotrophs (Hayashi 
et al., 1999b; Lee et al., 2000a).  Previously, we reported the creation of mouse 
lines expressing a human GH-1 transgene containing a G to A transition at the 5’ 
splice site of intron 3 (IVS3+1) that leads to exclusive production of the 17.5-kDa 
isoform (McGuinness et al., 2003).  This transgene is expressed from a cosmid 
containing the entire GH-1 locus control region including upstream DNA 
elements required for somatotroph-specific expression.  The IVS3+1 mutant 
exerts a dominant negative effect on wild type mouse GH and generates a 
transgene dose-dependent IGHD II phenocopy.  Even in the presence of two wild 
type mGH alleles, high copy transgenic mice exhibit IGHD II with concomitant 
reduced weight, severely reduced pituitary GH content, and progressive anterior 
pituitary hypoplasia (McGuinness et al., 2003; Ryther et al., 2003).  
Overproduction of the 17.5-kDa isoform triggers not only somatotroph death but 
also destruction of neighboring cells by macrophage invasion, leading to severe 
hypoplasia and additional anterior pituitary hormone deficiencies (McGuinness et 
al., 2003).  The 17.5-kDa isoform arises because the normal exon 3 splice sites 
are relatively weak with accurate splicing requiring the presence of at least 3 
splicing enhancer elements (Ryther et al., 2004).  Even in the normal pituitary, a 
small number of GH-1 transcripts (<1–3%) are incorrectly spliced and encode the 
17.5-kDa isoform (Procter et al., 1998).  Variability in the age of onset and 
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severity of IGHD II among patients is thought to be due to the amount of the 
17.5-kDa isoform relative to the full length, 22-kDa protein (Hayashi et al., 1999b; 
McGuinness et al., 2003; Millar et al., 2003).  These phenotypic differences may 
reflect a threshold and dose dependency of the amount of the 17.5-kDa isoform 
produced from mutated alleles, sufficient to cause somatotroph death and trigger 
pituitary defects (McGuinness et al., 2003).  Currently, recombinant hGH is used 
in replacement therapy for IGHD II to overcome short stature but is relatively 
expensive, can lead to unwanted side effects (Monson, 2003) and, importantly, 
does not prevent anterior pituitary hypoplasia and other ensuing anterior pituitary 
deficits (Mullis et al., 2005).  Since IGHD II arises as a direct consequence of 
excessive production of a specific dominant negative isoform, strategies 
designed to decrease levels of the 17.5-kDa isoform without affecting the normal 
22-kDa product could be an effective form of therapy.  Here we have used RNAi 
to specifically target the mutant GH-1 transcript encoding the 17.5-kDa isoform in 
vivo and we show rescue of IGHD II in a mouse model. 
 
Materials and Methods 
 
Cell Culture  
Wild type and Δ3 human GH cDNAs were cloned into pcDNA 3.1(+) 
(Invitrogen) as described (Deladoey et al., 2001) using identical primers.  
pSuper-sh17.5 was cloned as described (Ryther et al., 2003).  Mouse 
AtT20/D16v-F2 cells (EACC, UK) were grown in DMEM with 10% FBS and 1% 
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penicillin/streptomycin with 4.5g/L glucose.  Cells were transfected with hGH 
constructs and/or pSuper-sh17.5 using LT-1 (Mirus) according to the 
manufacturer’s protocol. 
 
RT-PCR 
RNA was isolated 48 hours post transfection using TRI-reagent (Molecular 
Research Center).  For analysis of human GH-1 splicing patterns in AtT20 cells, 
RT-PCR was performed as described (Ryther et al., 2003) with the exception that 
M-MLV reverse transcriptase (Promega) was used.  For analysis of pituitary 
RNA, 500ng total RNA was used for first strand cDNA synthesis with the 
following primer that recognizes both mouse and human GH sequences 5’-
CGGGGGCTGCCATCTTCCAGC-3’.  The same primer was used for PCR 
amplification with a 32P-labeled forward primer, 5’-
GCCTGCTCTGCCTGCYCTGGC-3’.  PCR products were separated on 6% 
denaturing polyacrylamide gels and visualized on a phosphorimager.  Amplifying 
both products with the same primers allows accurate quantitation within the same 
lane obviating the need for a loading control.  Results are thus shown as a ratio 
of the two products derived from a single lane.  
To assay possible interferon responses, first strand cDNA was 
synthesized using oligo d(T) with 2µg of total pituitary RNA.  Subsequent RT-
PCR amplification was done using: OAS-1-forward 5’-
CAGCCGTCAATGTCGTGTGTGATT-3’ and OAS-1-reverse 5’- 
TGTTAAGGAACACCACCAGGTCAG-3’.  
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Western Blots  
At-T20/D16v-F2 cells were lysed in 1x Laemmli loading buffer (LLB) 48 
hours post transfection.  Whole pituitaries were briefly sonicated in RIPA buffer 
(50mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM EDTA, 1% NP-40, 0.5% 
deoxycholate, 0.1% SDS) and mixed with an equal amount of 2x LLB.  All 
samples were denatured for five minutes at 95°C before loading onto 10% SDS 
gels.  After transfer, PVDF membranes were blocked with 5% milk and incubated 
with primary antibodies against hGH or α-tubulin (Abcam).  After incubation with 
HRP-conjugated secondary antibodies (GE Healthcare), proteins were visualized 
by ECL (Perkin Elmer Life Sciences). 
 
Transgenic Mice 
A Not1-Xho1 restriction fragment of pSuper-17.5 (Figure 15) was purified 
and used for pronuclear injection of C57BL/6 embryos.  Injections and oviduct 
transfers were performed by the Vanderbilt Transgenic Core Facility using 
standard techniques in accordance with protocols approved by the Vanderbilt 
University Institutional Animal Care and Use Committee (VU-IACUC).  
Transgenic mice were verified by PCR from tail DNA using primers: 5’-
GCTCTAGAACTAGTGGATCC-3’ (forward) and 5’-
CTAGAGTCTCTTGAACTCTAGG-3’ (reverse).  The sh-20 and sh-25 lines 
contain 3 and 7 copies of the transgene, respectively (data not shown).  
Transgenic mice were bred with wild type C57BL/6 mice. IGHD II mice were also 
bred with wild type C57BL/6 mice and transgenic animals were identified by 
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PCR, as described (McGuinness et al., 2003).  Progeny resulting from crosses of 
shRNA-17.5 mice and IGHD II mice were identified by PCR, using the same 
primers as above. Mice were weighed once a week from week 4 – 16 after 
weaning.  All mouse work was performed according to VU-IACUC guidelines and 
in accordance with VU IACUC protocol number M/05/075 
 
Pituitary Dissections 
Pituitaries were dissected from eight week-old mice, fixed in 4% 
paraformaldehyde in phosphate buffered saline.  Pituitaries were visualized with 
a Leica MZ16F scope and QImaging Retiga EXi camera.  
 
Immunohistochemistry and Imaging 
20µm cryostat sections from pituitaries of 10 week-old mice were 
subjected to fluorescent immunohistochemical staining using goat anti-mouse 
GH antibodies and Cy-3 conjugated anti-goat antibodies (Santa Cruz 
Biotechnology).   Pituitary sections were mounted in 50% glycerol and imaged 
with a Zeiss LSM510 Meta Laser Scanning microscope.  Stacks were acquired 
with LSM510 software, and Z-projections and contrast adjustments were made 
with NIH ImageJ.  See supplementary information for additional information 
concerning image acquisition. 
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Electron Microscopy 
Pituitaries from 10 week-old mice were fixed overnight in 2% 
glutaraldehyde.  Following washes in 1xPBS, pituitaries were transferred to 1% 
OsO4 for 1 hour before washing with dH2O.  Preparations were then stained en 
bloc in 1% aqueous uranyl acetate and dehydrated in an ethanol series, passed 
through propylene oxide, transferred to a 1:1 Spurr:propylene oxide mixture, and 
removed and embedded in Spurr’s embedding reagent. Ultra-thin serial sections 
(50-60nm) were obtained on a Leica UCT Ultracut microtome, transferred to 
formvar-coated grids, and examined on a CM10 Transmission Electron 
Microscope (FEI), operating at 80k and viewed on a Phillips CM10 TEM 
equipped with an AMT 2 mega pixel camera (AMT). 
 
IGF-1 Serum Analysis 
Serum was obtained by tail vein bleeding at weeks 8 and 16 post 
weaning.  Mouse IGF-1 levels were determined using a mouse IGF-1 ELISA 
(Immunodiagnostic Systems Inc.). 
 
Statistical Analysis 
Statistical significance between mice was determined for data points from 
week 16 for all growth curves and for IGF-1 serum data using a one-way ANOVA 
followed by a Tukey-Kramer HSD analysis (JMP, version 5.01).  Normal 
distribution for all data was determined by a Shapiro-Wilk’s test.  A summary of 
values used to determine statistical significance is listed in Tables 4-6. 
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Figure 14. Allele Specific RNAi in AtT-20 cells. (A) An shRNA (shRNA-17.5) 
was designed complementary to the unique exon 2-exon 4 junction (red bar) and 
expressed from a pSuper vector.  (B) AtT-20 cells were transfected with hGH 
cDNA constructs and pSuper-sh17.5, as indicated.  RNA was isolated and the 
different isoforms amplified by RT-PCR using primers in exon 2 and exon 5.  
Bands corresponding to the wild type product (22 kDa isoform) and the exon 3 
skipped product (∆3; 17.5 kDa isoform) are as indicated.  The percentage ± 
standard error of the ∆3 transcripts relative to wild type is shown below based on 
at least three independent experiments.  Quantitation is based on the ratio of 
products within a single lane and was calculated by phosphorimager 
densitometry.  (C) Western blots of cell lysates from the same transfections as in 
(B) were performed using antibodies against hGH or α-tubulin as a loading 
control. 
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Results 
 
Allele Specific Targeting of Mutant GH-1 Transcripts by RNAi 
Skipping of exon 3 produces hGH transcripts containing a unique 
sequence at the junction of exon 2 and exon 4.  We previously showed that 
shRNAs complementary to this unique sequence specifically target transcripts 
encoding the 17.5 kDa isoform (Δ3 transcripts) but do not alter wild type 
transcript levels (Ryther et al., 2004).  However, we did not examine the effects 
of the shRNAs on protein levels.  Therefore, we transfected At-T20 cells, a 
murine neuroendocrine cell line that does not produce endogenous growth 
hormone, with the vector encoding shRNA-17.5 (Figure 14) along with vectors 
expressing either wild type hGH or the IVS3+1 mutant that expresses only the 
17.5 kDa isoform.  Cells were harvested after 48 hours and analyzed for hGH 
protein and mRNA levels.  As shown, the shRNAs effectively decreased the 
levels of ∆3 transcripts without affecting full-length transcripts (Figure 14b).  
Interestingly, despite the fact that the experiment shown in Figure 14 did not lead 
to complete loss of ∆3 transcripts, there was a total absence of the 17.5-kDa 
isoform (Figure 14c).  In other experiments we do not always observe complete 
loss of the 17.5-kDa isoform.  Despite slight experimental variability, we conclude 
that expression of shRNA-17.5 results in significant allele specific silencing of ∆3 
transcripts and abrogation of the 17.5-kDa isoform.   
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Generation of shRNA-17.5 Transgenic Mice 
To test if shRNA-17.5 targets the mutant GH-1 allele in vivo, we generated 
mice expressing the shRNA by pronuclear microinjection of a 347 bp DNA 
restriction fragment of pSUPER-sh17.5 (Figure 15a,b).  Ten independent lines of 
shRNA-positive mice were generated (Table 3).  These mice show no differences 
in weight or lifespan as compared to wild type littermates, display no obvious 
phenotypes, and nine of the ten lines are fertile (Figure 15b).  While 
overexpression of shRNAs can lead to toxicity and lethality due to oversaturation 
of the endogenous microRNA (miRNA) pathway or due to possible off target 
effects (Grimm et al., 2006; Jackson et al., 2006b), the presence of the shRNA-
17.5 transgene did not induce any discernable effects in at least nine of the ten 
lines.  Also, we did not observe any induction of interferon responses, at least as 
measured by levels of 2’,5’-oligoadenylate synthetase (OAS1; Figure 15c), a key 
interferon responsive gene (Sledz et al., 2003).  
 
Rescue of IGHD II In Vivo by RNAi 
Mice expressing shRNA-17.5 were bred with the IGHD II mice to 
determine whether the IGHD II phenotype could be rescued in vivo (Figure 16a).  
Mice expressing both hGH-17.5-kDa and shRNA-17.5 showed rescue of the 
growth deficit compared to IGHD II littermates (Figure 16b, 17a).  Of the ten 
founder shRNA-17.5 transgenic lines, five have thus far been crossed and all 
rescue growth (Table 3).  Below, we more completely characterize two rescue 
lines.  The shRNA line 20 (sh-20) completely rescued the growth deficit with no 
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Figure 15. Generation of transgenic shRNA-17.5 mice.  (A) A Not I–Xho I 
fragment of pSuper-sh17.5 containing an H1 promoter driving expression of 
shRNA-17.5 was used for pronuclear injections to generate transgenic mice.  
The guide strand is highlighted.  (B) Transgenic shRNA-17.5 mice were identified 
by PCR.  (C),(D) Growth curves of transgenic sh-20 (C) and sh-25 (D) mice. 
Weights of transgenic mice (sh-20 line (n=4), yellow; sh-25 line (n=6), green) and 
wild type littermates (n=5 for each graph) (blue) were determined between 4-16 
weeks of age.  Error bars are ±s.e.m.  From ANOVA, p>0.7 for both data sets.  
Full statistical analyses are in Table 4. (E) Expression of shRNA17.5 does not 
elicit an interferon response.  RNA was isolated from pituitaries of the indicated 
genotypes and RT-PCR was performed using primers against the interferon 
induced gene, 2’, 5’-oligoadenylate synthetase (OAS 1) (left) and β-actin as a 
control (right).  sh-20 mice are shown in the top panel and sh-25 in the lower 
panel. 
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Table 3. Generation of transgenic shRNA-17.5 mice. Two sets (a, b) of 
pronuclear injections were performed to generate shRNA-17.5 transgenic 
founders.  Mice in bold have been shown to rescue a mouse model of IGHD II.   
shRNA mice 25a and 20b were selected for further analysis and were 
subsequently referred to as sh-25 and sh-20 respectively. 
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Figure 16.  Mating Strategy.  (A) Expected offspring from matings between 
IGHD II and shRNA-17.5 mice.  (B) Five week-old IGHD II, rescue (20R), and 
wild type littermates.  (C) Genetic assortment of progeny from matings of sh-20 
(yellow) or sh-25 (green) with IGHD II mice. 
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difference in weight compared to wild type littermates.  The shRNA line 25 (sh-
25) significantly improved weight-gain compared to IGHD II mice but did not fully 
attain normal levels (Figure 17a).  Both lines had lower weights at weaning but 
with time these increased as to be significantly greater than the IGHD II mice.  
For both lines, weight rescue was observed in both male and female progeny 
and was obvious at weaning (particularly in the sh-20 rescue line), as would be 
expected since this is when growth deficits become manifest in rodents.  The 
genotypes assorted close to the predicted Mendelian ratios among the progeny 
for both lines (Figure 16a,c).  
We next analyzed pituitary morphology and function for the sh-20 and sh-
25 rescue lines (20R; 25R).  Pituitary dissections revealed that the severe 
anterior pituitary hypoplasia observed in the IGHD II mice was not detected in 
either the 20R or 25R lines (Figure 17b).  Pituitaries shown in Figure 17 are from 
8 week old mice but the increase in pituitary size was observable at weaning (3 
weeks; data not shown).  Interestingly, considering the degree of weight rescue 
by the different lines, the anterior pituitaries from the 20R mice were smaller than 
the 25R pituitaries and remained so past 6 months in age.  No significant 
differences in anterior pituitary size were observed between wild type mice and 
the sh-20 and sh-25 transgenic lines.  As expected, the posterior pituitary was 
similar in size for all mice.  Since the IGHD II model mice exhibit pronounced 
somatotroph loss, we next sectioned pituitaries and performed fluorescent 
immunohistochemistry using an antibody that specifically recognizes mouse GH 
(mGH).  As shown in Figure 17c, the IGHD II mice had a severe decrease in 
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Figure 17.  Rescue of IGHD II mice. (A) Growth curves of wild type (blue, 
n=10), IGHD II (red, n=8), 20R (yellow, n=6), and 25R (green, n=4) mice.  (B) 
Pituitary dissections from eight week-old mice.  The posterior pituitary is 
indicated within the dashed line.  Scale bar at the upper left indicates 1mm.  (C) 
Fluorescent immunohistochemistry staining with anti-mGH on 20µm pituitary 
sections taken from 10 week old mice.  The posterior pituitary is indicated below 
the dashed line.  (D) Serum IGF-1 levels were measured by ELISA from 8 and 16 
week-old mice (n=3 for each genotype).  Wild type, blue; IGHD II, red; 20R, 
yellow; 25R, green.  Error bars are ±s.e.m. From ANOVA for A. and D. p<0.0001.  
For complete statistical analyses, see Tables 5 and 6. 
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Tables 4-6. Statistical analysis.  Summary of 95% confidence intervals, 
comparison of both pairs by Tukey-Kramer HSD and Shapiro-Wilk’s goodness of 
fit test for normal distribution of the values a week 16 in Figure 15c,d (Table 4),for 
values at week 16 in Figure 17a (Table 5) and for weeks 8 (top panel) and 16 
(lower panel) for data shown in Figure 17d (Table 6).  For all tables, groups with 
different letters are significantly different.  (α = 0.001) 
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mGH production, consistent with dominant negative effects exerted by the 
IVS3+1 mutant.  In contrast, the sh-20, sh-25, 20R and 25R lines all expressed 
mGH at levels indistinguishable from wild type.  Quantitative measurement of 
serum GH in single samples is uninformative due to the pulsatile nature of GH 
secretion.  However, long-term restoration of GH output should correct the low 
insulin-like growth factor 1 (IGF-1) levels observed in IGHD II.  IGF-1 is secreted 
in the liver in response to GH stimulation and low serum IGF-1 levels indicate GH 
deficiency (Clemmons, 2007).  Accordingly, serum IGF-1 levels were measured 
in groups of mice at 8 and 16 weeks of age.  As shown in Figure 17d, both 
rescue lines showed IGF-1 levels that were similar to wild type levels and 
significantly higher than the IGHD II mice.  At week 8, the IGF-1 serum levels in 
the 25R mice were slightly lower than the 20R and wild type mice but by week 16 
there were no significant differences in IGF-1 levels between the three 
genotypes.  These results are concordant with the weight trends where the 25R 
line rescues the IGHD II phenotype slightly less than the 20R line.  Interestingly, 
although the 20R mice have slightly greater weights and initially higher serum 
IGF-1 levels than the 25R mice, the 20R pituitaries are consistently smaller than 
the 25R pituitaries. 
 
Morphological Rescue of IGHD II 
Growth hormone is packaged into granules, forming dense-core secretory 
vesicles (DCSVs).  The specific mechanism responsible for the dominant 
negative nature of the 17.5-kDa isoform is not certain but may be due to 
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formation of 17.5:22-kDa dimers and oligomers which disrupt granule packaging 
thus preventing the secretion of either isoform from somatotrophs, ultimately 
triggering an unfolded protein response (McGuinness et al., 2003).  These 
complexes apparently overwhelm the degradative capacity of the proteosome, 
leading to the accumulation of toxic aggregates in the cytosol, ER and Golgi 
apparatus.  Consistent with this model, electron micrographs of anterior pituitary 
sections from IGHD II mice show Golgi and ER defects, loss of DCSVs and 
dramatically increased levels of intracellular lipid and vacuolation (McGuinness et 
al., 2003) (Figure 18a,b).  Wild type cells show a large accumulation of mature 
DCSVs that are stored and released upon appropriate hypothalamic stimulation.  
As is evident from the electron micrographs, secretory cells from the rescue mice 
have abundant DCSVs, comparable to wild type, with normal morphology (Figure 
18a,b).  Thus, our data from gross morphology to electron micrographs indicate 
that genetic delivery of shRNAs against transcripts encoding the dominant 
negative 17.5-kDa isoform is able to rescue growth and somatotroph function in 
IGHD II mice.  
 
Silencing of the 17.5 kDa Isoform 
Interestingly, despite the fact that we observed rescue of IGHD II with 
several transgenic shRNA-17.5 lines (Table 3), we have not been able to directly 
detect expression of the shRNAs.  We assume this is due to expression at levels 
below our current limit of detection and/or instability of the shRNAs.  Indeed, 
such low levels may preclude lethality and/or toxicity as reported by Grimm et al. 
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Figure 18. Morphological rescue of IGHD II. Electron micrographs of the 
anterior pituitaries from 10 week-old mice of the indicated genotypes.  Scale bar 
is 2µm;  magnification is (A) 10,500x and (B) 3,400x.  
 98 
(Grimm et al., 2006).  Nevertheless, we were able to show that the shRNAs are 
directly altering the levels of the 17.5-kDa isoform by examining pituitary GH 
RNA and protein levels in the rescue mice.  First, using primers that are 
complementary to both human and mouse GH transcripts, we performed RT-
PCR analysis to determine the relative levels of wild type, full length mGH mRNA 
compared to the levels of the ∆3 transcripts encoding the hGH 17.5-kDa isoform.  
As shown in Figure 19a, there was a dramatic change in the ratio of the two 
transcripts between the IGHD II mice and the rescue mice, consistent with the 
notion that rescue involves reducing levels of the ∆3 transcripts.  Bearing in mind 
that IGHD II mice have severely hypoplastic anterior pituitaries, western blots 
using antibodies that recognize both mouse and human GH showed that what 
little GH was produced was mainly the 17.5-kDa isoform (Figure 19b).  For the 
rescue mice, even though significant levels of the 17.5-kDa isoform were 
detected, the dramatic increase in full length, wild type mGH was apparently able 
to overcome any dominant negative effects exerted by the mutant, thereby 
rescuing growth and pituitary function (Figure 19b,c).  Thus, our biochemical and 
genetic results are completely consistent with functional reduction of the 17.5-
kDa hGH isoform to rescue the dominant negative phenotype. 
 
Discussion 
RNA interference has many potential advantages over traditional 
therapies, including increased specificity and versatility (Dykxhoorn et al., 2006; 
Kim and Rossi, 2007).  Many recent advances in RNAi therapeutics have been 
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Figure 19.  Silencing of the 17.5-kDa isoform.  (A) Total RNA was isolated 
from pituitaries of the indicated genotypes and RT-PCR was performed with 
identical primers that distinguish between mouse and human GH.  Bands 
corresponding to the full length spliced product from the mouse alleles (mGH) 
and the 17.5 kDa human transgene (hGH-17.5) are as indicated.  Quantitation of 
the two transcripts is based on the ratio of products within a single lane and was 
calculated by phosphorimager densitometry. (B) Western blots of pituitary lysates 
from the same genotypes as in (A) were performed with an antibody that 
recognizes both human and mouse GH.  The two upper panels were deliberately 
overexposed to allow visualization of the GH isoforms in IGHD II. (C) A shorter 
exposure (2 seconds) of the same gel shown in (B) (15 seconds). 
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used to successfully knock down viral genes or disease alleles though, to our 
knowledge, none have been used to knock out a dominant negative disease 
allele in an animal model.  These approaches have used either small interfering 
RNAs (siRNAs) or shRNAs to target relatively accessible tissues such as sub-
retinal injection into the eye (Reich et al., 2003), intranasal delivery to the lung 
(Bitko et al., 2005; Zhang et al., 2005), transfection via lipofectamine complexes 
to the vaginal epithelium (Palliser et al., 2006), tail vein injection to the liver 
(Morrissey et al., 2005b; Soutschek et al., 2004), viral delivery to the liver (Grimm 
and Kay, 2006) and viral delivery via intraspinal or intracranial injections (Ralph 
et al., 2005; Raoul et al., 2005; Xia et al., 2004).  Zimmermann et al. used 
systemic delivery of siRNAs in primates targeting ApoB in the liver by saphenous 
vein injection (Zimmermann et al., 2006).  By comparison, although it is not 
protected by the blood-brain barrier, the pituitary is relatively inaccessible to 
direct targeting due to its location.  We therefore decided to deliver shRNA-17.5 
via genetic means by making transgenic mice expressing the shRNAs.  Using 
this approach, we were able to specifically reduce expression of the dominant 
negative 17.5-kDa hGH isoform allowing recovery of wild type GH levels to 
rescue an autosomal dominant mouse model of human IGHD II.   
 A potential caveat to our results concerns the inability to directly detect 
expression of shRNA-17.5 precursors or mature siRNAs.  This could be used to 
argue that the effects we observe are indirect.  However, several lines of 
evidence argue against such a conclusion.  First, we have shown genetically that 
when IGHD II mice are crossed with shRNA mice, only the progeny that contain 
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both the shRNA transgene and the ∆3 transgene exhibit the rescue phenotype.  
From mating and genotyping over 400 mice, we only observed rescue in the 
double transgenics.  Also, the extent of the rescue varied between the different 
shRNA lines; the 25R lines exhibit slightly lower growth rates and initial IGF-1 
serum levels compared to the 20R lines (Figure 17 a,d and Table 3).  Second, 
the transgenic shRNA lines show no overt phenotype that could be responsible 
for or contribute to the rescue phenotype observed in the IGHD II background.  
Third, the genotypes assort in the expected Mendelian ratios (Figure 16c).  Thus, 
the genetics argue strongly against any indirect effect.  Biochemically, we also 
showed that in the IGHD II mice the predominant isoform is the dominant 
negative hGH 17.5-kDa protein whereas in the rescue mice there is a switch and 
the major protein detected is the wild type mGH (Figure 19b).  Together, these 
data support our conclusion that the rescue of IGHD II is a direct effect of 
shRNA-17.5.  
Future work will be directed toward a viable therapeutic strategy using 
exogenous delivery of siRNAs but the results from this report show that 
employing RNAi provides a promising approach to treat IGHD II in humans.  
While GH treatment can counteract GH deficits in children and adults with 
Growth Hormone Deficiency (GHD), the underlying somatotroph destruction 
continues with additional bystander effects that can evolve to damage other 
pituitary hormone axes in some individuals (Salemi et al., 2005).  A particularly 
encouraging feature of our results is the restoration of macroscopically and 
microscopically normal somatotroph populations in the rescue mice without any 
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overt phenotype in other cells.  Since normalization of somatotroph function 
offers a selective advantage in survival and replacement during somatotroph 
turnover, this promotes complete functional recovery without necessarily 
achieving complete suppression of the aberrant allele in every cell.  More 
generally, many human diseases result from aberrant splicing and/or dominant 
negative isoforms and our results show that RNAi offers a promising way to 
specifically degrade mutant alleles while sparing wild type, functional alleles. 
 
Acknowledgements 
This work was supported by NIH grant DK 035592 and by funds from the 
Vanderbilt Mouse Metabolic Phenotyping Center (DK 59637).  We thank Priscilla 
Dannies for wild type and Δ3 hGH cDNA constructs.  The authors would like to 
thank Alex Flynt for helpful discussions, Melissa Prince and Cindy Holladay for 
assistance with mouse maintenance, Elvin A Woodruff III for electron 
microscopy, Bryan Harris for help with mouse screening and Scott P. Egan for 
help with statistical analyses.  Fluorescent confocal microscopy was possible 
through use of Vanderbilt Cell-Imaging Shared Resource equipment and 
transgenic mice were created in the Vanderbilt Transgenic core.  
 103 
CHAPTER IV 
 
SUMMARY AND CONCLUSIONS 
 
Significance 
The research presented in this thesis demonstrates that RNAi can be 
used to effectively treat IGHD II. Importantly, RNAi treatment targets the 
underlying cause of the disease, overexpression of the 17.5-kDa hGH isoform.  
As such, this is an attractive alternative to the current treatment of subcutaneous 
recombinant GH injections, which does not prevent future hormonal deficiencies 
that can occur as a result of severe anterior pitiuitary hypoplasia.  Prior to this 
thesis, it was demonstrated that shRNA-17.5 could be used to degrade ∆3 
transcripts in tissue culture (Ryther et al., 2004).  Here, as a primary step in 
developing shRNA-17.5 as a viable therapeutic for patients with IGHD II, we 
examined its ability to rescue IGHD II symptoms in a model system.  To 
accomplish this, we used a transgenic mouse model of IGHD II where a human 
GH-1 mutant allele that exclusively produces the 17.5-kDa isoform is expressed.  
Though expressed in concert with two copies of wild type mGH, high copy 
numbers of the 17.5-kDa mutant cause severe IGHD II symptoms (McGuinness 
et al., 2003).  We made many lines of transgenic mice expressing shRNA-17.5 
and bred these mice with IGHD II mice.  Progeny with shRNA-17.5 in an IGHD II 
background exhibited rescued phenotypes that were similar to wild type 
phenotypes.  These phenotypes include growth rates, GH expression in the 
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anterior pituitary and levels of serum IGF-1 (Figure 17).  Rescue mice also 
showed normal gross and cellular morphology as determined by pituitary 
dissections and EMs of pituitary sections, respectively (Figure 17b, 18). 
 Many experimental questions abound in relation to delivery of siRNA-17.5 
to the pituitary.  These include time of delivery, quantity of siRNAs to administer 
and the number of repeated deliveries that will be required, in addition to 
addressing the issue of specific delivery to the pituitary.  Now that we have 
successfully shown functional rescue of IGHD II using RNAi, we are poised to 
address these points and develop siRNA-17.5 as a therapeutic. 
 IGHD II is caused by several different GH-1 mutations, mostly in and 
around exon 3 that cause exon skipping.  One consequence of using siRNA-17.5 
to degrade ∆3 transcripts is that it targets an aberrantly spliced isoform which can 
occur as a result of several different mutations, including the new mutation 
described in this thesis.  Since the abnormally spliced product caused by the 
mutation is being targeted, rather than the mutation itself, siRNA-17.5 could be 
used to treat all cases of IGHD II caused by exon 3 skipping and over production 
of the dominant negative 17.5-kDa isoform, providing a wider platform for 
therapeutic uses. 
As mentioned above, many mutations in and around exon 3 cause exon 
skipping.  In addition to showing rescue of IGHD II using RNAi, we have also 
identified and characterized a new mutation in the GH-1 gene in a family with 
autosomal dominant GHD.  Sequencing of patient DNA identified a G→A 
transition at the first base of exon 3 (Figure 10).  The first base of exon 3 
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corresponds to the 3’ splice site, AGG as well as the first base of ESE 1 and our 
analysis shows that this transition mediates its effects by affecting both of these 
elements.  By disrupting ESE 1 and by weakening the 3’ splice site consensus 
sequence, this mutation causes exon 3 skipping, resulting in an IGHD II 
phenotype.  In elucidating the mechanisms by which this mutation functions we 
have further emphasized the importance of splicing fidelity and the importance of 
multiple splicing signals in this process. 
  
Impact and Future Directions 
 
Phenotypic Characterization of Rescue Mice 
 
Pituitary Hormone Content 
 There is a profound loss of pituitary GH content in the mouse model of 
IGHD II containing high copy numbers of the ∆3-hGH transgene.  Dramatic 
reductions in levels of PRL and TSH are also observed in these mice and 
transgenic males also show a loss of LH though females do not (McGuinness et 
al., 2003).  In all cases, the loss of individual hormones is exacerbated with age.  
From an endocrine perspective, it will be interesting in the future to fully 
characterize the rescue mice.  Preliminary results from five-month old mice show 
a significant increase in pituitary GH content in both the 20R and 25R mice 
compared to the IGHD II mice (Figure 20).  Interestingly, the amount of GH in the 
rescue mice is approximately a sixth of that in wild type mice or in either of the  
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Figure 20. Analysis of pituitary hormone contents.  Adult mouse pituitaries 
were sonicated in cold PBS and hormone contents were assayed by RIA.  GH, 
left; PRL, right.  n=3 for each genotype 
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two transgenic shRNA (sh-20 and sh-25) lines.  This is most likely because the  
rescue mice are producing just enough GH to maintain normal growth such that 
as soon as GH is produced, it is secreted, hence the lower pituitary GH content.  
The ∆3 transgene contains multiple Pit-1 promoter sites and any physiological 
drive to increase mGH expression should also increase expression of the 
transgene, though it will be subsequently degraded by shRNA-17.5 in the rescue 
mice.  Conversely, the sh-20, sh-25 and wild type mice are able to produce and 
store ample amounts of GH.  The amount of pituitary PRL is extremely reduced 
in the IGHD II mice compared to wild type mice (Figure 20).  Our preliminary data 
do not suggest any significant difference in the levels of PRL in the rescue mice 
compared to control mice.  Apparently, although the rescue mice are not 
producing enough normal mGH (due to the expression of the 17.5-kDa isoform) 
to store abundant quantities like their wild-type counterparts, they are producing 
enough to prevent additional anterior pituitary hormone losses, specifically PRL.  
In addition to repeating this experiment, it will also be interesting to investigate 
the pituitary levels of TSH and LH, which have been shown to be deficient in the 
IGHD II model. 
 GH is released in pulsatile bursts and as such it is impossible to 
accurately quantify GH serum levels unless a stimulus is administered.  This 
procedure is routinely done in patients with suspected GHD and agonists include 
chlonidine and arginine (Table 2).  Subsequent serum analysis should show a 
peak GH level in response to the agonist.  Future work to analyze GH levels in 
the rescue mice should use similar provocation tests in mice, taking serum 
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samples before and after a large dose of GHRH which causes GH release into 
the blood, the peak height of which is roughly proportional to the pituitary reserve 
(Le Tissier et al., 2005).  The advantage is that this can be done in anaesthetized 
mice and would be a reliable serum GH assay to complement the serum IGF-1 
data shown in figure 17d. 
 
Effects on Bone Length and Mass 
GH and IGF-1 have well recognized effects on bone elongation during 
development and the large increase in bone mass that occurs during childhood 
and puberty via endochondrial bone formation is stimulated by these factors 
(Ohlsson et al., 1998).  Patients with GHD often exhibit decreased bone mineral 
density though the effects are significantly different depending on whether or not 
patients had childhood GHD or adult-onset GHD (Kaufman et al., 1992; 
Maheshwari et al., 2003).  Mean BMD increases during long-term GH 
replacement therapy and eventually reaches normal levels (Saggese et al., 
1996).  Since GH has such effects on longitudinal growth and bone mass, it will 
be interesting to assay any such effects in the IGHD II mice and determine if 
these effects are reduced or absent in the rescue mice.   
 
Developing siRNA-17.5 as a Therapeutic 
There are at least two main considerations in developing a viable siRNA-
based therapeutic to specifically target ∆3 transcripts.  The first involves 
determining the appropriate time to deliver siRNAs in relation to the onset of 
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IGHD II such that pituitary damage has not progressed so far as to prevent 
recovery.  The second consideration is to optimize specific delivery to the 
pituitary, which will likely prove a major obstacle in developing siRNA-17.5 
therapy, indeed all RNAi based strategies. 
 
Time of Delivery 
 To understand the developmental timing of pituitary damage in IGHD II 
mice, we sectioned pituitary tissue from newborn pups.   Electron micrographs 
showed morphological differences in IGHD II mice as young as one day 
compared to wild type mice (Figure 21).  Between the two, a distinct difference in 
the appearance of the ER was detected.  Somatotrophs from the mutant mice 
showed a distinct lack of ribosomes in the cytosol and an abundance of protein 
within the ER lumen (Figure 21a,b).  In contrast, the ER lumens from wild-type 
pituitaries were clear with readily detectable ribosomes in the cytosol.  An 
additional difference was the location of the DCSVs.  In somatotrophs from wild-
type mice, they appeared dense and were located throughout the cytosol 
whereas DCSVs in somatotrophs from IGHD II mice seemed to congregate 
toward the periphery of the cell, adjacent to the plasma membrane, were less 
dense, and had an ovoid appearance (Figure 21c).  Autophagic vesicles are also 
present in the mutant pituitaries and absent in wild-type samples.  Although there 
are phenotypic differences in wild-type and IGHD II mouse anterior pituitaries 
even at a young age (1 day), it is promising that the extreme vacuolation and 
gross abnormalities caused by somatotroph loss that are visible in eight-week old  
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Figure 21. IGHD II mice exhibit ER defects at a young age.  (A) Electron 
micrographs of pituitary sections from one-day old mice and (B) 21-day old mice.  
(C) Lower magnification of the same tissue shown in B. ER lumen, L; DCSV, DC; 
mitochondria, M.  Scale bar in (A) and (B) is 500nm and in (C) is 10µm. 
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mice do not appear to manifest themselves by three weeks, the time at which 
mice are usually weaned.  These observations suggest that it could be possible 
to treat IGHD II model mice with siRNAs at weaning.  Mice that are handled at 
younger ages can often be rejected by the mother so it would be beneficial to 
start siRNA delivery at weaning. 
In the IGHD II mouse model, there is a marked increase in GHRH 
expression and concurrent decrease in somatostatin expression, due to the 
feedback loop that regulates GH secretion (McGuinness et al., 2003).  It is 
postulated that early treatment of IGHD II with exogenous GH replacement 
therapy may be important in rescuing a degree of pituitary function by providing a 
feedback signal to reduce the GHRH drive, thus reducing somatotroph 
proliferation and rate of self-destruction (McGuinness et al., 2003).  In severe 
cases of IGHD II, such as our mouse model, the somatotroph damage leads to 
loss of other endocrine cells in the pituitary and their hormone production.  
Bearing these two aspects in mind, it would be advantageous to treat IGHD II 
mice with siRNA-17.5 as early as possible. 
  
Delivery of siRNAs to the Pituitary 
The pituitary is situated at the base of the brain, in the pituitary fossa, but 
is not protected by the blood brain barrier (BBB), which is only permeable to 
lipophilic molecules of less than 400 Da (Pardridge, 2002). This is therefore an 
advantage from the perspective of delivery of therapeutic molecules.  However, 
some of the methods developed to transport nucleic acids across the BBB could 
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be incorporated into designing siRNAs that target the pituitary.  One approach 
involves the use of molecular ‘Trojan horses,’ liposome complexes comprised of 
polyethylene glycol (PEG) where the nucleic acid is encapsulated within the 
liposome interior and thus insulated from nuclease degradation (Boado, 2007).  
In an elegant study targeting siRNAs to the central nervous system, ~1-2% of the 
PEG molecules of the nanoparticle were engineered with two different types of 
monoclonal antibodies.  These antibodies trigger receptor-mediated endocytosis 
across the BBB and also target a specific cell type (Zhang et al., 2004).  We 
could adapt this method by designing liposome complexes that contain a protein 
or peptide fragment that recognizes a somototroph-specific cell marker.  An ideal 
candidate for this could involve exploiting the interaction between GHRH and its 
receptor. This receptor is expressed on the surface of somatotrophs and would 
be an attractive target in designing a selective delivery system for siRNA-17.5.  
We recently isolated and cultured primary mouse somatotrophs and though they 
were only viable for approximately five days in culture, they could be a valuable 
tool in designing and determining the efficacy of GHRH-conjugated siRNA-17.5 
nanoparticles.  For example, by supplying exogenous GHRH to the culture 
media, we would expect to see an up-regulation of GH, which could be quantified 
by assaying GH-1 transcripts or levels of GH secreted into the media.  This could 
be used to identify an optimum peptide fragment of GHRH that would engage 
with the receptor.  Of note, although the GHRH receptor is mostly expressed on 
somatotrophs, it is also minimally expressed in tissues that exhibit autocrine GH 
secretion, for example breast tissue (Mukhina et al., 2004).  An obvious benefit of 
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providing cell-specific targeting, aside from the fact that it should drastically 
decrease the amount of siRNA required, is that it could potentially prevent 
unwanted and unforeseen off target effects that may occur in other cell types. 
 Initial testing of delivery methods could use fluorescently labeled siRNAs 
such that delivery and stability can be assayed.  Another alternative is to use a 
transgenic GFP mouse and deliver siRNAs that are complementary to GFP.  This 
would be a relatively simple approach to assay siRNA delivery and activity by 
visualizing GFP silencing in multiple tissues including the pituitary.  This would 
help address the issue of how often to administer siRNAs depending on the 
stability and packaging of the individual siRNA. 
 In the work presented above, shRNA-17.5 was expressed from birth and 
as such the rescue phenotype was both obvious and immediately evident.  If we 
are delivering the siRNA to postnatal IGHD II mice, they will already have 
developed some, albeit mild, adverse phenotypes.  How long will it take to 
observe a rescue phenotype upon systemic delivery?  As growth is a somewhat 
slow indicator, perhaps serum IGF-1 levels would provide a better initial indicator 
of rescue.  In mammals there is a burst of GH secretion at birth though the 
significance of this is not known (de Zegher et al., 1993; Giustina and Veldhuis, 
1998).  Following this spurt, GH secretion is decreased until later in development.  
Obviously, development in mice is much more rapid than in humans but this time 
lapse in GH secretion should allow us to treat mice with siRNAs at, or just prior to 
weaning.  Additionally, the pituitary is able to proliferate and regenerate cells and 
in GHD subjects, there is an increase in expression of GH-releasing factor 
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(GRF), producing a postnatal drive to proliferate.  In fact, even in mice that are 8 
weeks old, the pituitary still regenerates at a rate of ~2% per day.  In the IGHD II 
mice, as the newly proliferated somatotrophs also express the dominant negative 
17.5-kDa isoform, the effect is exacerbated as there is a continual drive to 
produce more of the toxic protein.  By supplying siRNA-17.5, it is hoped that the 
cells that are recovering will survive and persist, and eventually rescue GHD. 
 
Mechanism of the Dominant Negative Function of the 17.5-kDa Isoform 
The 17.5-kDa isoform acts as a dominant negative but it is not clear why 
this is so.  Several hypotheses, most notably those of Iain Robinson and 
colleagues (Lee et al., 2000; McGuinness et al., 2003), suggest that the 17.5-kDa 
isoform forms heterodimers with wild type GH and these are inefficiently 
condensed when forming DCSVs, causing an accumulation of protein in the 
Golgi and ER.  This triggers an unfolded protein response and production of the 
dimers ultimately exceeds the degradative capacity of the proteasome, becoming 
toxic to the cell (McGuinness et al., 2003).  Recent work in the cultured rat 
somatotroph line, GH4C1, has shown that the 17.5-kDa isoform is indeed 
degraded by the proteosome and that proteosome inhibition leads to prominent 
accumulation of the mutant GH protein (Kannenberg et al., 2007). 
It would be attractive to develop a system in which to study effects of the 
17.5-kDa isoform that is both effective and relatively simple.  One possibility is to 
use AtT-20 (AtT-20/D16v-F2) cells, a murine neuroendocrine cell line derived 
from a pituitary tumor that does not express endogenous GH but secretes ACTH 
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in the same fashion as GH is secreted from somatotrophs.  These cells have 
been successfully used to visualize localization of the 17.5-kDa isoform both 
alone and when co-expressed with wild type GH in relation to secretory 
components (Salemi et al., 2006).  AtT-20 cells can be stimulated with forskolin 
which increases cAMP levels and promotes ACTH secretion.  Forskolin has also 
been used to stimulate GH secretion in AtT-20 cells transfected with GH 
constructs (Salemi et al., 2006).  A disadvantage to making stable cell lines that 
constitutively express the 17.5-kDa isoform is that in the selection process, the 
cells expressing high copy numbers of the mutant will die since it is toxic and, in 
effect, we would be selecting for low levels of mutant expression.  We are 
therefore developing inducible stable cell lines that express either mutant, wild 
type or both GH constructs under the control of the Tet-responsive element 
(CloneTech), allowing transcription of these transgenes to be switched on in the 
presence of tetracycline.  These stable cell lines could be used to visualize 
secretory pathway defects in the ER and Golgi.  These cells could also provide 
an ideal system to study the unfolded protein response if indeed this is 
responsible for cell death.  
 
RNAi in the Pituitary 
 Though regulated by the hypothalamus, the pituitary itself controls 
secretion of the body’s hormones and is often referred to as the ‘master gland.’  
Many disease states have been characterized by decreased or absent hormone 
production, leading to hypopituitarism.  Conversely, pituitary tumors, or pituitary 
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adenomas, can result in hormonal overproduction that can also have detrimental 
consequences.  Excess of GH production can lead to acromegaly and excess 
PRL secretion can lead to infertility.  Imbalance in hormone production from the 
pituitary can lead to a number of endocrine disorders.  As discussed previously, 
there are other genetic disorders (other than mutations in GH-1) that can disrupt 
the GH-1 axis and any of these that function in a dominant manner are potential 
targets for treatment using RNAi.  As an example, Pit-1 is expressed in the 
pituitary and is epistatic to GH-1.  Two dominant mutations in Pit-1 have been 
characterized, P24L and R271W, that cause GHD (Ohta et al., 1992; Radovick et 
al., 1992), and these could be potential targets for RNAi-based therapies.  When 
the latter mutant, R271W, was co-transfected with wild type Pit-1, it prevented 
transcriptional activation by the wild type protein and acted as a dominant 
negative (Dattani and Robinson, 2000).  In IGHD II, anterior pituitary hypoplasia 
develops due to the dominant negative nature of the 17.5-kDa hGH isoform and 
its resulting toxic effects.  With the exception of our study, there have not been 
any published reports that use RNAi to target pituitary specific mRNAs.  With 
development of a sound and robust delivery system of siRNAs to target ∆3 
transcripts in the pituitary, we could open up a new avenue in RNAi therapeutics. 
 
Summary 
In closing, the data presented in this thesis highlight the importance of 
maintaining splicing fidelity to prevent exon skipping and the production of 
deleterious protein isoforms.  Where mistakes in GH-1 splicing occur and cause 
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skipping of exon 3, we have shown that expression of shRNAs that specifically 
target aberrant transcripts can rescue a disease phenotype in a mouse model of 
IGHD II.  Our approach involved genetic delivery of shRNAs but as work 
proceeds to develop systemic delivery methods, it seems clear that the ability to 
rescue disease using RNAi could usher in a new era in gene therapy. 
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